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Abstract
Background: Uveal melanoma (UM) is an extremely aggressive disease with
approximately 50% of patients developing incurable metastatic disease. Therefore,
accurate prognosis of a patient is necessary for closer follow up and the earlier
implementation of systemic adjuvant therapies in those most likely to develop metastatic
disease. Fortunately, UM can be classified into two distinct molecular classes based on
clinically validated gene expression profiling, chromosomal aberrations and specific
driver mutations, which accurately predict the metastatic propensity of the primary
tumour. However, genetic testing currently requires biopsy of the eye which can lead to
serious complications including permanent blindness. Therefore, an alternative source of
primary tumour genetic material is needed to avoid these complications.
Aims: We proposed that circulating tumour cells (CTCs) are a viable source of tumour
genetic material in which patient prognosis could be analysed. Firstly, we aimed to
increase the sensitivity of an immunomagnetic enrichment protocol to capture CTCs.
Secondly, we aimed to evaluate whole genome amplification methods for accurate single
cells analysis to determine the genomic profile of UM cells. The combination of both
aims would allow the use of UM CTCs for determining disease prognosis from an easily
accessible blood sample.
Methodologies: Aim 1 - To refine and evaluate methods for multi-marker
immunomagnetic capture of UM CTCs. A tissue microarray (TMA) was created from
1mm cores taken from archived primary UM tissue. Normal tissue and cutaneous
melanoma were added as controls. The TMA was stained by immunohistochemistry
(IHC) for melanoma, melanocyte, and stem cell markers. Stained tissue was assessed to
determine intensity and coverage of staining. In addition to primary UM tissue, five UM
cell lines were assessed for the same markers using flow cytometry and
immunocytochemistry. Given their high level of staining of UM, 5HT2B, ABCB5,
surface gp100 (BETEB), MCAM, and MCSP were coated to immunomagnetic beads and
used to determine the retrieval rate of UM cell lines cells spiked into peripheral blood
mononuclear cells at a known quantity. CTCs could be detected by immunofluorescent
staining of MART1, gp100, and S100β.
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Aim 2 - Aim 2: To develop methodologies for the detection of genetic markers of
metastatic propensity using single UM cells. Single UM cell line cells plus respective
bulk genomic DNA whole genome amplified and bulk genomic DNA were amplified
using PicoPlex and Repli-G WGA kits to determine each kits’ respective viability of
detecting CNVs using low-pass (0.01-0.1x) whole genome sequencing (WGS) on the
IonPGM platform. Peripheral blood mononuclear cells (PBMCs) were used as negative
controls. In addition, we tested if these methods allowed accurate CNV data after fixation,
permeabilisation, and immunostaining. After ensuring cell processing had no significant
effects on genomic profile of single cells, blood samples from patients were processed to
isolate CTCs from PBMCs. Isolated CTCs were then whole genome amplified using
PicoPlex and shallow sequenced using the IonPGM system.
Results: We validated several melanoma, melanocyte, and stem cell markers which have
been previously shown to be expressed in cancer, cutaneous melanoma, or UM. We found
that 5HT2B, and ABCB5, surface gp100 (BETEB), MCAM, and MCSP were highly
expressed in primary UM tissue or UM cell lines and were able to immunomagnetically
capture UM cell line cells. Concurrently, we validated the use of shallow (0.01x-0.1x
depth) whole genome sequencing of single UM cells amplified using the PicoPlex WGA
Kit and found that PicoPlex offered a robust method of amplifying single cells that have
undergone immunomagnetic isolation, fixation, staining, and capture whilst retaining the
original genetic profile of the parent cell line. Upon testing this in a patient, we found a
gain of chromosome 8 which is an early event in UM tumourigenesis; aneuploidy of
chromosome 8 is a genetic feature that may, with the aid of future studies, delineate
patient metastatic risk.
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Conclusion: Herein we validated several melanoma, melanocyte, and stem cell markers
to increase the rate and number of CTCs captured from patients with primary UM. We
then further validated the use of shallow (0.01-0.1x) WGS to detect CNVs in single cells
amplified using PicoPlex. We have optimised and validated a pipeline, involving
separation of CTCs from PBMCs via a multi-marker immunomagnetic captured method
targeting 5HT2B, ABCB5, surface gp100 (BETEB), MCAM, and MCSP and detection
via immunostaining of MART1, gp100, and S100β. Once isolated and immunostained,
single CTCs are captured, whole genome amplified using PicoPlex, and sequenced on the
IonPGM system to detect CNVs relevant to patient prognosis. This easier, more
accessible way of detecting patient metastatic risk may enable patients to enrol in clinical
trials, allow doctors to prescribe potential adjuvant therapies, and facilitate closer followup.
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1.0 Introduction
Uveal melanoma (UM) is the most common intraocular malignancy in adults
(McLaughlin et al., 2005). In Australia, it affects approximately 8.55 individuals per
million per year (Vajdic et al., 2003). After detection of metastasis, 92% of patients die
within two years. Moreover, approximately 50% of those diagnosed with localised UM
develop incurable metastatic disease (Kujala et al., 2003). Although the treatment of
localised UM has improved over the last 30 years, current treatment has little effect on
the development of metastatic disease and survival rates have not changed (Singh et al.,
2011).
To improve patient outcomes, detection of those with the highest risk of developing
metastasis is necessary to implement early treatment interventions. Many cytogenetic
features are able to accurately predict UM patient prognosis and propensity of the tumour
to metastasise (Aalto et al., 2001; Harbour et al., 2010; Martin et al., 2013; Onken et al.,
2004; van Raamsdonk et al., 2009; van Raamsdonk et al., 2010). However, current genetic
analysis of the tumour requires direct biopsy of the eye, which can lead to serious
complications such as retinal detachment, vitreous haemorrhage, and permanent
blindness (Pereira et al., 2013). An alternative source of tumour genetic material can be
found in circulating tumour cells (CTCs) which may allow analysis of the genetic
determinants of metastatic propensity by means of a ‘liquid biopsy.’ However, current
methods for the determination of these markers of metastatic disease in UM CTCs need
to be developed and evaluated. Here we evaluated markers for UM CTC isolation and
detection, as well as developed methods to determine genetic aberrations within single
UM CTCs, to produce a robust protocol for determining the metastatic propensity of
patients with primary UM tumours from a blood test.
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2.0 Literature Review
2.1 Structure of the Eye and Uvea
The eyes are complex, fluid filled organs. They average 24mm in diameter (Martini et al.,
2015) and resemble a small irregular spheroid. Three layers of tissue encase the fluid
filled cavity; an outer fibrous layer (sclera), an intermediate vascular layer or uvea (iris,
ciliary body, and choroid) and an inner layer (retina) (Figure 1).

Figure 1: Anatomy of the Eye. Sagittal section of the eye, showing the internal
structures (Gray, 1918). Structures commonly affected in UM are the iris, ciliary body
and choroid.
The uveal or vascular layer is comprised of the iris, ciliary body, and choroid. This layer
is responsible for the regulation of light entering the eye, a route for blood vessels that
service the surrounding tissue, secretion and reabsorption of aqueous humour, and the
control of lens shape (Martini et al., 2015). More importantly, the uveal layer contains
melanocytes which dictate eye colour and absorption of light (Martini et al., 2015). The
2

malignant transformation of these melanocytes results in the formation of UM from either
the anterior (iris) or posterior (ciliary body or choroid) uveal tract, with the majority
arising in the choroid (COMS-20, 2003; McLaughlin et al., 2005).

2.2 Uveal Melanoma Epidemiology and Clinical Prognosis
2.2.1 Epidemiology
UM is the most common intraocular malignancy in adults and the second most common
form of melanoma (McLaughlin et al., 2005). The incidence of UM differs worldwide. In
the United States, the incidence is around 5 cases per million (Singh et al., 2011).
European incidence has a north-south gradient decreasing from >8 in northern countries
to <2 cases per million in southern countries (Virgili et al., 2007). In a similar fashion to
cutaneous melanoma, the incidence of UM in the Australian population is higher than the
rest of the world with approximately 8.55 per million for UM (Vajdic et al., 2003). The
age of diagnosis of UM ranges from 6-100 years, with a median age of 62 years (Singh
et al., 2011). Interestingly, patients ≤20 years of age appear to have significantly higher
incidence of iris UM compared to those aged ≥21 (Shields et al., 2012). The importance
of gender in UM is contested in the literature; two studies showed higher incidences of
UM in males compared to females (Singh et al., 2011; Virgili et al., 2007), while a third
study did not note any significant difference between the genders (Shields et al., 2012).
Lastly, Caucasian populations are predominantly affected in comparison to other races
and ethnicities (Chang et al., 1998; Singh et al., 2011).
2.2.2 Risk Factors for Primary Uveal Melanoma
There are several factors that lead to a predisposition in the development of UM, which
can be divided into host and environmental factors. Host factors may include light eye
colour, fair skin colour, and the inability to tan (Weis et al., 2006). Additionally, preexisting naevi, the naevus of Ota (Shields et al., 2015; Singh et al., 1998; Singh et al.,
2005; Sumich et al., 1998), and germline BAP1 mutations (Goldstein, 2011; Ismail et al.,
2014) increase the risk of developing UM. Environmental factors include exposure to
ultraviolet (UV) light from arc welding as a significant risk factor, while chronic UV and
occupational sun exposure are marginal factors (Shah et al., 2005); , latitude and leisurely
sunlight exposure are not significant risk factors (Shah et al., 2005).
3

2.2.3 Prognosis: Clinical and Histopathological Features
At the time of initial diagnosis of UM, approximately 4% of patients have detectable
metastasis (Finger et al., 2005). However, metastasis of UM occurs in approximately 50%
of all patients (Jovanovic et al., 2013). UM metastasises via haematogenous
dissemination, with the most common site of metastasis being the liver followed by the
lungs and bone (COMS-15, 2001). Nevertheless, UM has been shown to metastasise to
the brain, skin and any other location within the body (COMS-15, 2001). The median
time from diagnosis of metastasis to death is <6 months, with the death rate of patients
being 80% within one year, and 92% within two years after detection of metastasis
(COMS-26, 2005).
Large tumour basal diameter (Figure 2A) (Kujala et al., 2003) and tumour thickness
(apical height) (Figure 2B) (Shields et al., 2009) are associated with the development of
metastatic disease and ultimately with poorer survival (Shields et al., 2007). Similarly,
the presence of extraocular extensions has also been shown to correlate with increased
mortality due to its association with increased tumour malignancy and more advanced
disease (Coupland et al., 2008). However, Coupland et al. (2008) noted that the size of
the extraocular extensions did not have any impact on mortality. Tumour size is
incorporated into the COMS staging system (Appendix 8.5) and all of the above clinical
features are incorporated into AJCC staging system (Appendix 8.6). These are the two
most common methods of describing the stages of UM, and aid in the determination of
patient prognosis (COMS-5, 1997; COMS-17, 2001; Kaliki et al., 2015; Shields et al.,
2013). Patient age at time of diagnosis is another predictive feature, with >60 years being
more closely associated with metastasis and death (Shields et al., 2012). Other clinical
features of UM that predict prognosis of patients are ciliary body location, tumour colour,
presence of subretinal fluid and intraocular haemorrhage (Shields et al., 2009).
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Figure 2: Size and Thickness of Primary Uveal Melanoma Tumours and Their
Association with Overall Survival. A) Cumulative incidence estimate of melanoma
mortality based on largest basal diameter of the primary tumour. Adapted from (Kujala
et al., 2003), and B) cumulative survival probability graph showing the effects of tumour
apical height on survival. Adapted from (Shields et al., 2009).
Histopathological characteristics of the primary tumour provide information in regards to
patient outcome and tumour metastatic propensity. Cell type is one distinct prognostic
factor. There are two major types of cells involved in UM, spindle (Figure 3A and B)
and epithelioid (Figure 3C). The loss of cohesion, larger and rounder nucleus, coarse
chromatin, eosinophilic nucleolus, occasional multinucleated cells, and higher mitotic
rate are all features that distinguish epithelioid cell type from spindle cell type (McLean
et al., 2004). The presence of the epithelioid cell type by itself or in a mixed morphology
(Figure 3D) has a significantly worse prognosis than that of the spindle cell type (Paul et
al., 1962). In addition, the prognosis becomes poorer with increasing numbers of
epithelioid cells per high power field (Seddon et al., 1987). Another predictor of prognosis
is tumours with higher mitotic activity (McLean et al., 1977). Ki-67 is used to determine
mitotic rate and it has been noted that high levels of Ki-67 in UM are associated with
shorter survival (Karlsson et al., 1996).

5

Figure 3: Haematoxylin-Eosin Staining of Uveal Melanoma Tumours with Distinct
Cell Types. A-B) Spindle-cell type A and B, C) epithelioid cell type and D) mixed cell
type. Adapted from images from http://www.eyecalcs.com/DWAN/pages/v9/v9c020.html
Vascular features are also used in prognostication of patients. The intravascular presence
of tumour cells is one histopathological prognostic parameter, with UM cell growth into
vessels inside the tumour and vessels outside the tumour, or in both, are associated with
a poorer survival than those without (Ly et al., 2010). Another vascular parameter useful
in predicting the prognosis of patients with UM is the presence of vascular networks.
Folberg et al. (1992; 1993) identified nine distinct vascular patterns with the presence of
vascular networks, defined by three back to back vascular loops, correlating with the
highest risk of metastatic death. Microvascular density has been also found associated
with the presence of microvascular loops and networks, epithelioid cells, largest basal
tumour diameter, and overall survival (Makitie et al., 1999).
Lastly, the presence of tumour infiltrating lymphocytes can be used to determine
prognosis. M2 macrophages (CD68+, CD168+, and CD68+ CD168+) are the primary type
of infiltrating macrophage in UM and have been shown to be increased drastically in
tumours with monosomy of chromosome 3. M2 macrophages are associated with ciliary
body involvement, increased microvascular density and significantly poorer prognosis for
6

survival (Bronkhorst et al., 2011). Additionally, class I and II HLA expression are also
linked to the levels of immune cell infiltration, with lower levels of HLA expression
correlating with lower levels of tumour infiltrate (de Waard-Siebinga et al., 1996).
The use of these clinical and histopathological markers as predictors of patient outcomes
is problematic, due to the broad variability and no unified staging system (Werdich et al.,
2013). Therefore, the use of genetic markers for the analysis of UM may provide a more
accurate and objective prediction of the risk of metastatic disease.

2.3 Molecular Characteristics of Uveal Melanoma
2.3.1 Gene Expression
Comparison of gene expression signatures of primary tumour lesions from patients that
developed metastasis with those that did not, demonstrated that UM can be organised into
two distinct molecular classes - class I or class II tumours. Each class displays distinct
clinical prognostic factors (Figure 4). The largest difference in expression comes from
down-regulation of chromosome 3 genes and up-regulation of chromosome 8q genes
(Onken et al., 2004). While class I expression reflects that of normal neural crest derived
melanocytes, class II corresponds with an up-regulation of epithelial genes, causing these
tumours to exhibit epithelial features such as polygonal cell morphology, up-regulation
of epithelial cadherin (E-cadherin), colocalization of E-cadherin and β-catenin to the
plasma membrane, and the formation of cell-cell adhesion and acinar structures (Onken
et al., 2006). Conversion to this epithelial phenotype may be a precursor of a metastatic
cell type (Onken et al., 2006).
These gene expression profiles were used to develop a clinically validated test called
DescisionDx-UM, incorporating 12 class discriminating genes and three endogenous
controls (Appendix 8.2) (Harbour and Chen, 2013). The test has a success rate of >97%
and can be performed on tissue samples obtained by fine needle biopsy, resection, and
enucleation (Field and Harbour, 2014). The result of this test classifies patients into class
I or II categories, and guides the intensity of metastatic surveillance and can be used to
determine whether the patient should be placed directly onto adjuvant systematic therapy
(Field and Harbour, 2014).
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Figure 4: Prognostic Differences between Class I and Class II Tumours. Survival
probability between class I and class II gene expression in 50 UM patients. All deaths
were caused by melanoma metastasis. Significant differences in survival between the
classes of tumour were found (P=0.01). Adapted from (Onken et al., 2004).
Whilst the bulk of patients who develop metastasis harbour a class II gene expression
profile, there are a subset of class I tumours that also give rise to metastasis. Therefore,
class I tumours are subgrouped into ‘1a’ and ‘1b’ based on the different expression of
epithelial cadherin (CDH1) and Ras-related protein Rab-31 (RAB31) (Field et al., 2016).
Moreover, the presence of Preferentially Expressed Antigen in Melanoma (PRAME)
mRNA is differentially expressed between these two subroups of class I tumours, with
0% 5 year rate of metastasis of Class IPrame- and 38% of Class IPrame+ (Field et al., 2016).
The use of gene expression profiling in primary UM can accurately predict the prognosis
of patients, however, it requires biopsy of the primary tumour within the eye which can
lead to complications such as vitreous haemorrhage, retinal detachment, and permanent
blindness (Pereira et al., 2013).
2.3.2 Chromosomal Aberrations
UM displays a lack of genomic instability and aneuploidy compared to other cancers
(Cross et al., 2003; Papadopoulos et al., 2002). Thus, chromosomal abnormalities found
consistently in UM are thought to be drivers of tumourigenesis rather than unconnected
random events. Specific chromosomal abnormalities, defining distinct prognostic and
metastatic risks (Aalto et al., 2001), allow for a more accurate prognosis in comparison
with current histopathological measures.
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Monosomy of chromosome 3 is a common genetic aberration found in UM, occurring in
approximately 50% of patients (Hoglund et al., 2004). In addition, monosomy 3 is able
to predict patient prognosis (Figure 5A) (Prescher et al., 1996; Shields et al., 2011; White
et al., 1998), as tumours with monosomy 3 have a significantly higher rate of metastasis
when compared to tumours with disomy 3 (Prescher et al., 1996; Tschentscher et al.,
2001). Moreover, monosomy of chromosome 3 is also associated with clinical and
histopathological features such as large tumour diameter, epithelioid cell type, ciliary
body involvement, vascular loops (Prescher et al., 1996; Scholes et al., 2003) and an
inflammatory phenotype (Herwig and Grossniklaus, 2011; Maat et al., 2008).

Figure 5: Worst Survival for Patients with Changes in Chromosome 3 and 8q. A)
Monosomy 3 (n=43) is a significant prognostic feature when compared to disomy 3
(n=23) (P<0.0001) in patients B) Patients with normal (n=14), gain, (n=24), or
amplification (n=28) of 8q show significant differences in survival between the three
categories (P<0.0001), between normal vs amplification (P<0.0001), between gain vs
amplification (p=0.00125), however, normal vs gain was only trending toward
significance (P=0.07). C) Lastly, monosomy 3 combined with 8q amplification (n=24)
had significantly increased risk of death to metastasis (P=0.011) when compared to
monosomy 3 combined with 8q gain (n=16) or monosomy 3 combined with normal 8q.
Adapted from (Versluis et al., 2015).
Chromosome 8 is another non-random chromosomal aberration described in UM. Gains
in copies of the long arm of chromosome 8 (G8q) can occur through isochromosome
formation, unbalanced translocations, and gain of a complete chromosome 8, and are
present in approximately 40% of UM cases (Hoglund et al., 2004), and are associated
with reduced survival and reduced disease-free interval (Figure 5B) (Sisley et al., 1997).
Aalto et al. (2001) found that 53% of metastasising primary tumours and 100% of
metastases harboured gains in 8q. Additionally, deletions in 8p12-22, containing leucine
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zipper tumour suppressor-1 (LZTS1), were also associated with quicker onset of
metastasis, and thus higher metastatic efficiency (Onken et al., 2008). Karyotyping has
shown that monosomy of chromosome 3 and gain of 8q correlate closely with
metastasising UM, and tumours with a combination of both mutations exhibit a worse
prognosis than those with each individual aberration alone (Figure 5C) (Dono et al.,
2014; Versluis et al., 2015). Additionally, monosomy of chromosome 3 and gain in 8q in
UM together with a large basal tumour diameter and extracellular matrix patterns show
significantly reduced metastasis free survival (van Beek et al., 2014).
Chromosome 6 is another prognostically relevant marker in UM. Losses in 6q are
associated with a poorer prognosis (Aalto et al., 2001). Inversely, gain in 6p is associated
with a better prognosis (Damato et al., 2009; White et al., 1998). Additionally, the gain
of 6p and monosomy of chromosome 3 appear to be mutually exclusive, with only 4% of
cases showing monosomy of chromosome 3 and gain of 6p, although, no prognostic
information was derived from this finding (Ehlers et al., 2008).
Loss of heterozygosity of chromosome 1p is an indicator of poor prognosis in tumours
that also show concurrent monosomy of chromosome 3 (Hausler et al., 2005; Kilic et al.,
2005). In particular, chromosome 1p36 primarily modified the survival of patients with
monosomy of chromosome 3, with patients who harboured both losses having 7.8 times
the risk of developing metastases (Kilic et al., 2005). Chromosome 1p loss also occurs in
40% of tumours with monosomy 3, and in 10% of tumours with disomy 3 (Hausler et al.,
2005). Identification of genes on 1p31 showed reduced expression of Integrin Beta 3
Binding Protein (ITGB3BP), while expression of Phosphodiesterase 4B (PDE4B), and
Interleukin 12 Receptor Subunit Beta 2 (IL12RB2) was absent in tumours with monosomy
3, indicating that these genes may influence progression of UM but are unlikely to be
driver mutations (Hausler et al., 2005).
Chromosomal aberrations are powerful tools for the determination of metastatic
propensity. A simple clinically validated test that is able to accurately determine copy
number variations is the multiplex ligation-dependant probe analysis (MLPA), with
results being highly predictive of patient survival (Damato et al., 2010; Lake et al., 2011;
Vaarwater et al., 2012). However, as for gene expression profiling, biopsy of the primary
tumour is required, and in addition to complications of the eye, various factors can affect
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the assessment of chromosomal aberrations, particularly a tumour’s cellular heterogeneity
and sampling errors, resulting in normal disomy 3 cells diluting tumour derived
monosomy 3 cells (Damato et al., 2009). For example, fine needle aspiration biopsies
may miss the most aggressive parts of a tumour due to the heterogeneous nature of tumour
cells, impacting the results of chromosomal aberration prognostic testing techniques such
as MLPA (Damato et al., 2009) or fluorescence in situ hybridisation (Chang et al., 2013;
Mensink et al., 2009).
2.3.3 Genes Mutated in Uveal Melanoma
2.3.3.1 GNAQ and GNA11
Mutations in Guanine nucleotide-binding protein subunit α-Q (GNAQ) and Guanine
nucleotide-binding protein subunit α-11 (GNA11) are common in UM (van Raamsdonk
et al., 2010), which are found at 9q21.2 and 19p13.3 (Versluis et al., 2015). These genes
encode similar Gqα subunits that consist of helical and catalytic GTPase domains (Figure
6) (Harbour and Chao, 2014).
Mutations to these genes cause the encoded receptor to be locked in an active state (van
Raamsdonk et al., 2010). The constitutive activation of this receptor causes activation of
the mitogen-activated protein kinase (MAPK) pathway (Bauer et al., 2009), a pathway
found activated in cutaneous melanoma (Zuidervaart et al., 2005). The MAPK pathway
is a key regulatory pathway that controls embryogenesis, cell differentiation, cell
proliferation, and cell death (Pearson et al., 2001).

Figure 6: GNAQ and GNA11 Protein Map and Location of Somatic Mutations in
Uveal Melanoma. GNAQ and GNA11 protein domains. Commonly mutated sites in UM
are indicated. Adapted from (Harbour and Chao, 2014).
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GNAQ and GNA11 somatic mutations appear to be mutually exclusive (Harbour and
Chao, 2014), with 83% of UM harbouring mutations in either gene (van Raamsdonk et
al., 2010). Two locations for driver mutations, within the switch regions, have been
described (Figure 6) (van Raamsdonk et al., 2009; van Raamsdonk et al., 2010), with
GNAQ harbouring Q209P, Q209L, Q209R (Bauer et al., 2009), or R183Q mutations (van
Raamsdonk et al., 2010). Similarly, GNA11 harbours Q209L, Q209P, R183C, or R183H
mutations (van Raamsdonk et al., 2010). The GNAQ and GNA11 Q209 mutations are
found in approximately 45% and 32% of primary UM, and in 22% and 57% of UM
metastases respectively (van Raamsdonk et al., 2010). R183 mutations in GNAQ or
GNA11 are found in approximately 2% and 3% of primary UM respectively, and in 6%
of metastases (van Raamsdonk et al., 2010).
Mutations in either GNAQ or GNA11 are found in all stages of UM, but show no
correlation with patient survival (Koopmans et al., 2013). As further evidence for this
lack of correlation, mutations in either gene can be found in benign blue naevi (van
Raamsdonk et al., 2009). GNAQ and GNA11 mutations are thought to be early or initiating
events in UM tumourigenesis, and are found in class I and II tumours (Harbour et al.,
2013), supporting the fact that they alone are not responsible for metastasis.
2.3.3.2 PLCB4
Phospholipase C Beta 4 (PLCβ4) is located on chromosome 20p12. The encoded protein
is responsible for the hydrolysis of phosphatidylinositol 4,5-bisphosphate into 1,4,5inositol trisphosphate and 1,2-diacylglycerol, vital components of signal transduction in
the light response in vertebrate retinas (Alvarez et al., 1995; Anderson and Brown, 1988).
The synthesised 1,4,5-inositol trisphosphate is now free to diffuse and binds to its
associated receptor causing increased intracellular Ca2+ levels, whilst 1,2-diacylglycerol
remains associated to the membrane, and with increased Ca2+ levels causes the activation
of protein kinase C (Lyon and Tesmer, 2013). This has been associated with cell
proliferation and survival (Lyon and Tesmer, 2013), and is a downstream target of
GNAQ/GNA11 (Johansson et al., 2016; Lyon and Tesmer, 2013).
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Recently, deep sequencing of UM revealed recurrent mutations (D630Y) in PLCβ4s
highly conserved Y domain (Figure 7) responsible for transduction of extracellular
signals in approximately 7% of samples. Mutant PLCβ4 were mutually exclusive to
GNAQ and GNA11 mutations (Johansson et al., 2016).

Figure 7: PLCβ4 Protein Map and Location of Somatic Mutations in Uveal
Melanoma. PLCβ4 protein domains with the location of the D630 driver mutation.
Adapted from UniProt.
2.3.3.3 CYSLTR2
Cysteinyl leukotriene receptor 2 (CYSLTR2) is found on chromosome 13q14. It is a seven
transmembrane G protein coupled receptor, and known activator of GNAQ (Evans, 2002;
Sakmar, 2002).
Recurrent mutations in CYSLTR2 were recently discovered in UM at codon L129 with a
substitution of L129Q, located in helix 3 (H3) (Figure 8), which is part of the receptor
that contacts the extracellular ligand, associates with other helixes, and interacts with the
Gα subunit intracellularly causing its constitutive activation (Moore et al., 2016). In this
same study, it was found that CYSLTR2 mutations followed the same mutual exclusivity
pattern found in GNAQ, GNA11, and PLCβ4 and were mutated in approximately 3% of
samples (Moore et al., 2016). Overall, mutations in GNAQ/GNA11, PLCβ4, and
CYSLTR2 are mutually exclusive and are all confined to the same proliferative pathway,
resulting in its constitutive activation (Figure 9).
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Figure 8: CYSLTR2 Protein Map and Location of Somatic Mutations in Uveal
Melanoma. CYSLTR2 protein domains and the location of L129Q somatic mutation.
Adapted from UniProt.

Figure 9: Interactions between Four Common Genes with Recurrent Mutations.
GNAQ/GNA11, PLCβ4, and CYSLTR2 protein interactions. Adapted from (Moore et al.,
2016).
2.3.3.4 BAP1
Another commonly mutated gene in UM is BRCA1 associated protein 1 (BAP1) which
encodes a nuclear ubiquitin carboxy-terminal hydrolase (UCH) (Jensen et al., 1998). The
protein consists of UCH catalytic domain, BARD1 binding domain, HCF1 binding motif
(HBM), BRCA1 binding domain (B), and nuclear localization sequences (NLS) (Figure
10) (Harbour and Chao, 2014).
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Figure 10: BAP1 Protein Map and Location of Somatic Mutations in Uveal
Melanoma. BAP1 protein domains with somatic mutation profile in UM. Non-truncating
mutations (small bars) and truncating mutations (large bars) are displayed. Adapted from
(Harbour and Chao, 2014) and UniProt.
UCHs are part of the deubiquitinating enzyme protein subfamily (Nishikawa et al., 2009).
There are four known members of the UCH subfamily: UCH-L1, UCH-L3, UCH37, and
BAP1 (Misaghi et al., 2009). Breast cancer 1 (BRCA1) is a tumour suppressor gene that
when transcribed, helps mediate the repair of double strand DNA breaks, chromatin
remodelling, cell cycle checkpoints, transcription, apoptosis, and centrosome duplication
regulatory functions. BAP1 interacts with the RING finger domain of BRCA1, with the
suggestion that BAP1’s carboxyl-terminus is bound to BRCA1 leaving the UCH catalytic
domain free to interact with ubiquinated, or other ubiquitin like, substrates to remove
them from the proteasome complex (Jensen et al., 1998). BAP1 binding to BRCA1 is
shown to increase the cell growth suppressive qualities of BRCA1 (Nishikawa et al.,
2009). In addition to binding to BRCA1, the BAP1 enzyme removes ubiquitin moieties
from histone H2A and host cell factor 1 (HCF1) (Harbour and Chao, 2014). It is also
noted that although ubiquitin can be used to direct proteins for degradation, BAP1 appears
to also affect gene expression, cell cycle, and cellular identity (Eletr and Wilkinson, 2011;
Harbour and Chao, 2014). The BAP1 protein is a tumour suppressor, and is found
inactivated in other cancers (Misaghi et al., 2009). Most importantly, repair of double
strand breaks is the mechanism by which BAP1 exerts its tumour suppressing activity
(Yu et al., 2014).
Mutations affecting the protein encoded by BAP1 were found in 84% of class II
metastasizing UM tumours, and cause premature protein termination or affect the
ubiquitin carboxyl terminal hydrolase domain (Figure 10). Class I tumours were shown
to rarely have BAP1 mutations (Harbour et al., 2010). BAP1 is found at 3p21.3 (Jensen et
al., 1998), so the loss of chromosome 3 could explain the known relationship between
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loss of heterozygosity (LOH) of chromosome 3 and metastasis of UM, with BAP1
undergoing inactivating mutations in one copy, and loss of the other copy by
chromosomal deletions (Harbour and Chao, 2014).
3.3.5 SF3B1
Splicing factor 3B, subunit 1 (SF3B1) is located at 2q33.1 (Yang et al., 2013) and the
protein consists of a U2AF2 interaction motif, PPP1R8 binding domain, SF3B14
interaction motif, and 22 non redundant HEAT domains (Figure 11) (Harbour and Chao,
2014; Wang et al., 1998). SF3B1 has been implicated more recently in UM. This gene
has been shown to harbour driver mutations in its HEAT domains, consisting of single
nucleotide point mutations primarily at amino acid R625 (Figure 11) (Harbour et al.,
2013; Martin et al., 2013), encoding R625H (63%), R625C (27%), R625G (5%), and
R625L (5%) mutations (Harbour et al., 2013).

Figure 11: SF3B1 Protein Map and Location of Somatic Mutations in Uveal
Melanoma. SF3B1 protein domain with the mutation profile of driver mutations found
in UM. The most common mutation site is noted by the large pin and less common
mutation sites by the small bars. Adapted from (Harbour and Chao, 2014; Wang et al.,
1998), and UniProt.
The mutations are usually heterozygous and are generally mutually exclusive with BAP1
mutations but occur with equal frequency in GNAQ versus GNA11 mutated tumours.
Mutations in SF3B1 are associated with class 1b tumours (Field et al., 2016), and disomy
of chromosome 3 which is associated with a lower risk of metastasis (Tschentscher et al.,
2001) and better survival rates (Prescher et al., 1996).
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2.3.3.6 EIF1AX
Eukaryotic translation initiation factor 1A, X-linked (EIF1AX) is located at Xp22 (Martin
et al., 2013). It encodes a protein responsible for the transfer of the Met-tRNAf to 40 S
ribosomal subunits prior to mRNA binding to form the 40S pre-initiation complex
(Chaudhuri et al., 1997). The protein consists of an N-terminal tail, oligonucleotide
binding (OB) fold, and C-terminal tail (Figure 12) (Harbour and Chao, 2014).
Mutations in EIF1AX has been reported in cases of UM as hemizygous missense
mutations in tumours with disomy of chromosome 3, with all mutations causing in-frame
changes that affect the N-terminus of the protein (Figure 12) (Martin et al., 2013). In
addition, tumours with EIF1AX mutations lacked SF3B1 mutations (Martin et al., 2013),
indicating that these mutations are mutually exclusive. Furthermore, it has been shown
that only mutant EIF1AX mRNA transcripts are expressed, pointing to epigenetic
inactivation of the wild-type copy of EIF1AX (Harbour and Chao, 2014). As for SF3B1
mutations, EIF1AX is associated with class I tumours (Harbour and Chao, 2014), disomy
of chromosome 3 (Martin et al., 2013), and better prognosis (Harbour and Chao, 2014).

Figure 12: EIF1AX Protein Map and Location of Somatic Mutations in Uveal
Melanoma. EIF1AX protein domain with the mutation profile of driver mutations in UM.
Small bars indicate small substitutions or deletions of 1-2 amino acids in the N-terminal
tail. Adapted from (Harbour and Chao, 2014).
Almost 100% of UM harbour a hotspot mutation in either GNAQ, GNA11, PLCβ4, or
CYSLTR2. Although they offer no information regarding patient prognosis, they present
a marker for use in methods such as droplet digital PCR (ddPCR), which is able to detect
mutations found in cell-free and circulating tumour DNA (cfDNA and ctDNA
respectively). Previous research has shown ctDNA correlates closely with tumour burden
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(Ascierto et al., 2013; Sanmamed et al., 2015), this enables ctDNA to work as a surrogate
biopsy for measuring tumour burden.
These key mutations and chromosomal aberrations assist not only with the diagnosis of
UM, but also with prediction of metastatic propensity. Routine identification of these
mutations may allow clinicians to determine the optimal treatment regimen for each
individual patient. Examples of this are targeted therapies in cutaneous melanoma, with
genetic testing of mutations in v-Raf murine sarcoma viral oncogene homolog B (BRAF)
used in the determination of first-line treatment options (Spagnolo et al., 2015), and in
UM many clinical trials are using genetic mutations as rational for targeted treatment
therapies (Appendix 8.3).

2.4 Uveal Melanoma Treatments
Radiation or enucleation are the main treatment options for localised UM, with the
majority of patients undergoing radiation treatment, saving enucleation for patients with
large tumours in which radiation cannot reduce the tumour sufficiently (Yonekawa and
Kim, 2012). Brachytherapy is the most common method used for treatment of choroidal
melanoma (COMS-19, 2002); this method involves suturing a radioactive plaque onto the
sclera, positioned behind the primary tumour for localised irradiation (Yonekawa and
Kim, 2012).
Proton beam irradiation is the next most common treatment option, and unlike
brachytherapy, the radiation is highly localised. Regression of tumours is shown by about
six months, and regression continues following this time (Wilkes and Gragoudas, 1982).
Recurrence rates are lower in patients receiving proton beam treatment (COMS-19,
2002). Radiation retinopathy leading to blindness is one complication of radiation
therapy, where radiation causes endothelial damage and capillary occlusion, resulting in
retinal haemorrhage, macular oedema, vascular sheathing, microaneurysms, retinal
exudation, telangiectasia, retinal pigment epithelial atrophy, and cotton wool spots
(COMS-30, 2009).
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The use of systemic chemotherapies, to treat metastatic UM, appears to have no benefit.
Combinations of lomustine, hydroxyurea, dacarbazine, Bacillus Calmette-Guerin
vaccine, zinostatin, dibromodulcitol, dihydroxy anthracenedione, and aziridinyl
benzoquinone have been trialled, however, no patients with metastatic ocular melanoma
responded to treatment (Albert et al., 1996). As UM has a propensity to metastasise to the
liver, several regional treatments of metastasis have been explored. These include liver
resection (Mariani et al., 2009), chemo-embolisation (Sharma et al., 2008), and isolated
hepatic perfusion (Ben-Shabat et al., 2015).
The use of therapies targeted to specific mutant proteins has been lacking until recently,
due to unknown mutations in UM. However, this is now changing as a result of recent
findings, with many targeted therapies entering clinical trials (Appendix 8.3) (Harbour
and Chao, 2014). One example of recent advances in targeted therapies includes drugs
targeting the Mitogen-activated protein kinase kinase (MEK) protein downstream of
GNA11 and GNAQ (Harbour and Chao, 2014); a recent phase II trial using a MEK
inhibitor extended progression free survival in patients by nine weeks when compared to
standard temozolomide chemotherapy (Selumetinib, 2013). Using histone deacetylase
inhibitors may be another potential therapeutic strategy. Recently, it was shown that
histone deacetylase inhibitors in cells with loss of BAP1 induced morphological
differentiation, cell cycle exit, and reversion to melanocytic gene expression profile in
UM cell lines (Landreville et al., 2012).
Ipilimumab immunotherapy has also recently been used in the treatment of UM. A recent
phase II trial of ipilimumab in advanced UM patients showed median overall survival of
6.8 months compared to median overall survival of <6 months without treatment, with
47% of patients having stable disease, and none experiencing partial or complete response
(COMS-26, 2005; Zimmer et al., 2015). A retrospective study of local treatments
including ipilimumab, bevacizumab and kinase inhibitors was performed at the Mayo
clinic. It was found that localised therapies were the only therapies to significantly
improve survival, although, the patients in the trial had better prognostic markers at
diagnosis of metastasis (Moser et al., 2015).
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Ipilimumab, bevacizumab, and kinase inhibitors had a positive effect on survival, but did
not reach statistical significance when used in patients with metastatic disease (Moser et
al., 2015). Another immunotherapy involves targeting programed death receptor 1 (PD1) and programed death ligand 1 (PD-L1). A recent trial evaluated the efficacy of PD-1
blockade in patients with metastatic UM. Out of 58 patients, only 2 (3.6%) had an
objective response and 5 (9%) patients had stable disease for ≥6 months. The median
progression free and overall survival were 2.6 and 7.6 months respectively (Algazi et al.,
2016). The poor response to immunogenic therapies may indicate that UM lacks the
immunogenicity found in other tumour types susceptible to immunotherapies. A recent
study investigated the immunologic composition of UM metastasis, and found that the
UM tumour infiltrating lymphocytes were CD4+ dominant, with discovery of a small
subset of UM patients harbouring more antitumour infiltrating lymphocytes, comparable
to patients with cutaneous melanoma, and correlating to the level of pigmentation found
in the tumour using MRI (Algazi et al., 2016). Therefore, overall outcomes may improve
in patients with this small subset of immunogenic UM, if detected and treated via
immunotherapies.
Patient death occurs from metastasis of the primary tumour. In addition to the treatment
information described above, previous reports have evaluated the effects of treatments for
patients with metastatic disease and found no compelling evidence to suggest that
treatment of patients with UM provides any survival benefit (Augsburger et al., 2009).
Therefore, implementation of adjuvant therapies to prevent metastasis, or to manage
progression of microscopic or macroscopic metastasis may be required to improve patient
outcomes.
A literature review of historical randomised and non-randomised trials for adjuvant
therapies (6 therapy types, from 1990-2009) revealed no difference in survival outcomes
post adjuvant therapies. However, these trials predate routine genetic testing currently
used to predict patient prognosis, and may not be targeting patients at a high risk of
metastasis, and therefore may be statistically underpowered (Triozzi and Singh, 2014).
Current adjuvant therapy trials pre-screen patients based on the genetic profile of the
primary tumour, to identify those at a high risk of developing metastases. Review of
clinicaltrials.gov reveals 4 active studies (Appendix 8.4) that attempt to prevent
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metastasis, and one study that aims to prevent metastatic recurrence using tyrosine kinase
inhibitors, cytotoxic chemicals or through biological interventions.
Another literature review suggests that other drugs may be also be useful as adjuvant
therapies, particularly histone deacetylase inhibitors (Landreville et al., 2012), DNA
methyltransferase inhibitors (Alcazar et al., 2012; Triozzi et al., 2012), MAPK inhibitors
(Kirkwood et al., 2012), or MEK/tyrosine-protein kinase Met (MET) inhibitors
(Chattopadhyay et al., 2014), due to their effects in either in vitro studies against UM cell
lines or in pre-clinical trials. It is expected that some of these therapies will be tested in
clinical trial in the near future. This underscores the need for methodologies to enable
stratification of metastatic risk in the majority of patients with localised uveal melanoma.

2.5 Circulating Tumour Cells
2.5.1 Features, Identification, and Capture of Circulating Tumour Cells
Circulating tumour cells (CTCs) are tumour cells that have circulated into the peripheral
blood of cancer patients, mediating metastatic dissemination. There are many studies
evaluating the prognostic value of CTCs in patients with a variety of cancers. In metastatic
prostate cancer (de Bono et al., 2008) for example, varying stages of small-cell lung
cancer (Hou et al., 2012), metastatic colorectal cancer (Cohen et al., 2008), and metastatic
breast cancer (Cristofanilli et al., 2004), higher levels of CTCs were associated with
significantly reduced overall survival. Furthermore, CTCs are now recommended by the
American Society of Clinical Oncology for the clinical staging of breast cancer (Harris et
al., 2007).
As the presence of CTCs has proven useful in determination of prognosis in other cancers,
investigation of CTCs in patients with UM may be a useful prognostic marker. Originally
detection of CTCs via reverse transcriptase-polymerase chain reaction (RT-PCR) was a
common method, targeting Tyrosinase (Boldin et al., 2005), MART1 (Schuster et al.,
2007), and gp100 (Keilholz et al., 2004) mRNA in either a single or multi-marker
approach. However, RT-PCR is an indirect measure of the presence of CTCs and cannot
be used to concurrently demonstrate the presence of CTCs, nor does it provide genotypic
and phenotypic information of the CTCs Moreover, RT-PCR cannot differentiate
between CTCs and circulating RNA, and is prone to high background and nonspecific
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amplification (Kowalewska et al., 2006; Paterlini-Brechot and Benali, 2007). Therefore,
immunomagnetic methods of detecting CTCs were developed to allow for the isolation
of intact cells.
By targeting melanoma-associated chondroitin sulphate proteoglycan (MCSP)
conjugated to immunomagnetic beads, 1-5 CTCs were detected in 50 mL of peripheral
blood in 19% (10/52) of patients with primary UM (Ulmer et al., 2008). The presence of
the CTCs was associated with ciliary body invasion, advanced tumour stage, tumour basal
diameter >14mm, and anterior tumour localization, which are all noted features in UM
progression (Ulmer et al., 2008). Similarly, another study showed that 14% (13/94) of
patients with primary UM have detectable CTCs prior to treatment (Suesskind et al.,
2011). However, Suesskind et al. (2011) found that there was no association between the
levels of CTCs and the propensity of the tumour to metastasise over a short median
follow-up of 16 months.
The use of immunomagnetic beads coated with melanoma cell adhesion molecule
(MCAM) for CTC isolation, followed by detection with MCSP immunostaining to
confirm CTC status, increased the rate of CTC detection (50%) in primary UM patients,
with more than 1 CTC captured per 7.5mL of blood (Bande et al., 2015). Interestingly,
Band et al. (2015) noted that a higher level of CTCs (3/7.5mL) was found in a patient
with a larger UM that harboured extrascleral extension and epithelioid pathology.
Nevertheless, a single marker approach for CTC isolation is not sufficient for detecting
CTCs in all patients.
To overcome the low sensitivity of a one marker approach, a dual immunomagnetic
enrichment protocol was developed. Using two antibodies recognising the melanoma
markers CD63 and glycoprotein 100 (gp100) (NKI/C3 and NKI/BETEB respectively)
enabled the detection of CTCs in 94% (29/31) of patients with a median cell density of
3.5 cells per 10 mL of blood, with a cell range of 0-10.2 cells (Tura et al., 2014). In a
follow-up study, 91% of patients (40/44) were found to have a median cell density of 2.4
per 10 mL of blood, with a range of 0-10.2 cells (Tura et al., 2016).
More recently, filtration based protocols have been described. As CTCs are generally
larger than surrounding leukocytes (Mazzini et al., 2014) they are able to be collected via
size based filtration. When this method was used, UM CTCs were identified in
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approximately 50% (15/29) of patients with localised disease. The presence of CTCs did
not associate with any clinical or pathological parameter, however, it was found that >10
CTCs per 10 mL of blood was a negative prognostic marker of disease-free and overall
survival over a 24 month period (Mazzini et al., 2014). As this method filters on the basis
of size, CTCs that are too small may be missed or normal cells that are clumped together
may be kept.
The levels of CTCs in the peripheral blood have provided conflicting results in the
determination of patient prognosis. Independent of the prognostic value of CTC
quantification, genetic testing of well characterised prognostic markers in individual
CTCs may provide more reliable information. However, the rate of CTC retrieval in
patients requires improvements.
Table 1: Additional Potential Markers for Use in Immunomagnetic Capture of
Uveal Melanoma Circulating Tumour Cells
Name

Site (Potential Use)

Description

ATP-binding cassette sub-

Membrane

In UM, ABCB5 is expressed in both pigmented and non-pigmented cells, with ABCB5

family B member 5

(Capture)

having preferential expression at the leading edge of the tumour (Thill et al., 2011).
ABCB5 is expressed in cutaneous melanoma CTCs (Freeman et al., 2012; Gray et al.,

(ABCB5)

2015a).
CD271 (NGFR)

Membrane

In UM, 3D cell culture conditions that facilitated vascular mimicry patterns expression

(Capture)

of CD271 was observed (Valyi-Nagy et al., 2012). CD271 is also expressed in cutaneous
melanoma CTCs (Freeman et al., 2012; Gray et al., 2015a).

5-Hydroxytryptamine

Membrane

In UM, expression profiling showed 5HT2B was significantly upregulated in UM liver

receptor 2B (5HT2B)

(Capture)

metastases (Zhang et al., 2014) and is one of the class discriminating genes in the
DecisionDx-UM test (Harbour and Chen, 2013). Its expression in cutaneous melanoma
or associated CTCs is unknown.

Receptor activator of NF-

Membrane

In cutaneous melanoma, RANK is involved in migration and metastasis of tumour

κB (RANK)

(Capture)

epithelial cells (Kupas et al., 2011), and is expressed in CTCs (Freeman et al., 2012;
Gray et al., 2015a; Kupas et al., 2011). Its expression in UM is unknown.

Melanoma associated

Membrane

MAGEA3 is expressed in approximately 50% of cutaneous melanoma (Vourc'h-

antigen 3 (MAGEA3)

(Capture)

Jourdain et al., 2009) and associated CTCs (Hoshimoto et al., 2012). It has not been
tested in UM or UM CTCs.

Nestin

Intracellular

Cytoplasmic Nestin staining is positive in 76% of cells, predominantly in nonpigmented

(Quantification)

cells in UM (Thill et al., 2011), and in cutaneous melanoma CTCs (Fusi et al., 2011).

Melanoma antigen

Intracellular

MART1 is expressed by melanoma cells and melanocytes with high levels in early stage

recognised by T cells

(Quantification)

melanosomes and associates with differentiation and melanogenesis (Zhang et al.,

(MART1)

2013). It is expressed in cutaneous melanoma CTCs (unpublished data), and in UM
CTCs (Schuster et al., 2011).

S100

Intracellular

S100 is detected in cells at all stages of liver metastasis in UM (Grossniklaus, 2013). It

(Quantification)

is also a melanogenesis marker.
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A multi-marker immunomagnetic bead approach for CTC capture and collection has been
described by our lab in cutaneous melanoma (Freeman et al., 2012). This approach to
CTC collection provided a considerable improvement in the sensitivity of CTC collection,
in comparison with single marker approach (Freeman et al., 2012). Current literature
describing markers for immunomagnetic capture of UM is limited, with studies using
either MCSP (Suesskind et al., 2011; Ulmer et al., 2008), MCAM (Bande et al., 2015;
Bidard et al., 2014), or gp100 (Tura et al., 2014) for isolating CTCs, and two different
markers for quantification by immunostaining of captured CTCs, including MCSP
(Bidard et al., 2014; Suesskind et al., 2011; Tura et al., 2014; Ulmer et al., 2008), and
gp100 (Tura et al., 2014).
Although MCSP has been shown to be expressed in 95% of primary UM (Li et al., 2003),
and although the specificity of MCSP is high, to improve sensitivity, targeting of
additional or other markers expressed in UM CTCs may be required to improve the low
rate of capture (14-19%) (Suesskind et al., 2011; Ulmer et al., 2008). Furthermore, there
are several other markers that may be useful (Table 1) in the immunomagnetic capture
of UM CTCs due to their common expression in either cutaneous melanoma or UM.
2.5.2 Genetic Features of Circulating Tumour Cells
CTCs may constitute a source of tumour DNA reflecting the genetic landscape within the
primary tumour (Heitzer et al., 2013a) and have recently been used to detect tumour
specific mutations (Gasch et al., 2013; Heitzer et al., 2013a; Maheswaran et al., 2008).
Single colorectal cancer CTCs were detected using an immunomagnetic method, then
isolated by micromanipulation and amplified via whole genome amplification (WGA).
The resultant WGA-DNA was sequenced and detectable mutations in Kirsten Rat
Sarcoma Viral Oncogene Homolog (KRAS) and Phosphatidylinositol-4,5-Bisphosphate
3-Kinase Catalytic Subunit Alpha (PIK3CA) were identified in metastatic cases (Gasch
et al., 2013). In a follow-up study, WGA-DNA of single CTCs was analysed for tumour
specific copy number variations (analysed by comparative genomic hybridisation (CGH))
and driver mutations, analysed by ultra-deep sequencing, presently identified in both the
primary tumour and metastases. In addition, mutations found initially only in CTCs were
also discovered at subclonal level in both the primary tumour and metastases (Heitzer et
al., 2013a). Furthermore, in this same study it was shown that the average copy number
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profiles from 10 captured CTCs showed similarities between the solid tumours and the
CTC copy numbers (Heitzer et al., 2013a).
Similar to the above, Ulmer et al. (2004) used MCSP to immunomagnetically capture
CTCs from patients with cutaneous or uveal melanomas that had either localised or
metastatic disease. A single UM CTC was isolated by micromanipulation and analysed
by CGH.

Genetic abnormalities associated with poor prognosis in UM such as

monosomy of chromosome 3 was detected in this cell. More recently, CTCs were isolated
from patients using gp100 and CD63 followed by fluorescence in-situ hybridisation to
detect chromosome 3 copy numbers. It was found that in 10/11 cases tested, the status of
chromosome 3 correlated with its status in the primary tumour (Tura et al., 2016).
Adding to the evidence that UM CTCs can act as a source of genetic material, it has been
shown that genetic mutations within the primary are also present within metastases (Singh
et al., 2009; Trolet et al., 2009); UM is a relatively stable malignancy (Cross et al., 2003),
and as UM spreads by haematogenous dissemination (Tulley et al., 2004), CTCs released
into the blood may harbour these mutations. As the genotype of UM can accurately
predict the metastatic propensity of the primary tumour, detection and isolation of single
CTCs could allow for an accessible and accurate method of prognostication.
In addition to CTCs, circulating tumour DNA (ctDNA) has been used to provide another
means of non-invasive analysis of tumour characteristics (Bettegowda et al., 2014; Bidard
et al., 2014; Dawson et al., 2013). These ctDNA manifests as a result of apoptosis and
necrosis of tumour tissue (Alix-Panabieres et al., 2012), and should therefore encapsulate
the genetic landscape of all tumours within the body. Due to a high proportion of recurrent
hot spot mutations in GNAQ, GNA11, PLCβ4, and CYSLTR2, detection of ctDNA is
easily possible in UM. Bidard et al., (2014) detected ctDNA in 84% UM patients with
metastatic disease, with ctDNA levels correlating with miliary hepatic metastasis,
metastasis volume and number of CTCs. Detectable ctDNA correlated with a poor
prognosis (Bidard et al., 2014). However, the presence of ctDNA has not been yet
evaluated in patients with localised UM.

25

3.0 Theoretical Framework
Given that approximately 50% of patients diagnosed with localised UM develop
incurable metastatic disease (Jovanovic et al., 2013) and within two years, 92% of patients
with detectable metastasis will die (COMS-26, 2005). It is therefore important to
determine early whether a patient will develop metastatic disease. Armed with such
knowledge, clinicians can evaluate adjuvant therapies at an earlier stage to prevent the
development of metastases.
Histopathological features combined with molecular analysis are now able to accurately
predict prognosis. Research into the expression of genes in UM has revealed two distinct
classes with distinct/specific genetic aberrations and these are significantly associated
with metastatic propensity (Figure 13). Current molecular prognostic testing, however,
requires sampling of the primary tumour and due to the inherent complications of direct
biopsy of the eye, such as vitreous haemorrhage, retinal detachment, and permanent
blindness (Pereira et al., 2013), an alternative source of tumour DNA for genetic analysis
is desirable. In this regard, CTCs may provide a suitable sample with which to assess the
genetic characteristics of the tumour for determining the metastatic potential of the
patient’s UM. However, the methods to carry out this analysis have yet to be rigorously
evaluated.

Figure 13: Key Genetic Events in Uveal Melanoma Tumourigenesis. Diagram
displaying the bifurcated progression pathway and a review of the key events in UM
tumour formation and metastasis described on the literature review.
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3.1 Hypothesis
CTCs are a suitable source of tumour DNA for the analysis of genetic markers of
metastatic propensity in patients with UM.

3.2 Aims
The overall aim of this project is to refine and evaluate methods for analysing genetic
characteristics that predict metastatic propensity using CTCs from patients with UM.
Aim 1: To refine and evaluate methods for multi-marker immunomagnetic capture
of UM CTCs.
Aim 2: To develop methodologies for the detection of genetic markers of metastatic
propensity using single UM cells.
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Abstract
Despite excellent local control of the primary tumour approximately 50% of uveal
melanoma (UM) patients will develop incurable metastatic disease. The stratification of
UM patients into groups with better or worse prognosis is based on clinicopathological
and molecular features and is critical for both patient management and for directing
patients towards clinical trials. However, the classification of tumours is constrained by
the invasiveness of the biopsy procedure and the limited availability of tissues when
enucleation is not performed. Here we evaluate the feasibility of using circulating tumour
DNA (ctDNA) and circulating tumour cells (CTCs) for molecular characterisation of UM
in patients with localised disease. ctDNA was quantified using droplet digital PCR for
detection of GNAQ and GNA11 Q209L mutations. Only 19% (5/27) of cases had
detectable ctDNA. CTCs were immunocaptured from the blood of 23 primary UM
patients by targeting the melanoma-associated chondroitin sulphate proteoglycan
(MCSP). This resulted in the isolation of 1-37 CTCs from 15 (65%) patients, an
inadequate efficiency for diagnostic use. As previous studies of cutaneous melanomas
had indicated greater capture rates by targeting multiple rather than single markers, the
expression of uveal and cutaneous melanoma specific markers was examined in UM
primary tumours and cell lines. We found heterogeneous expression of common markers
used for capturing CTCs in the tissue microarray (TMA) and cell lines. Markers such as
MCSP, MCAM, or surface gp100 were heterogeneously expressed at a moderate to high
level. In contrast 5HT2B and ABCB5 showed higher expression in tissue than in cell lines
and MCSP was absent in the TMA but present in cell lines. This indicates that due to the
heterogeneous nature primary UM, targeting of multiple surface markers and cytoplasmic
markers would improve capture and detection of CTCs in patients. Immunomagnetic
capture of UM cells using MCAM, MCSP and surface gp100 (BETEB) provided high
recovery rates of UM cells. These findings suggest that combinations of antibodies would
increase the efficacy of CTC capture in UM patients, allowing for molecular analysis to
derive critical prognostic information.
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Introduction
Uveal melanoma (UM) is the most common intraocular malignancy and the leading cause
of death due to primary intraocular disease in adults (McLaughlin et al., 2005). Despite
successful control of the primary tumour, incurable metastatic disease will ultimately
develop in up to 50% of patients (Blum et al., 2016). Extensive analysis of primary UMs
has defined molecular features of the tumour cells that predict, with a high degree of
accuracy, a patient’s risk for development of metastases. Biomarkers of poor prognosis
include histopathological features of the tumour, loss of chromosome 3, gain in
chromosome 6p and 8q (Damato et al., 2010), as well as the differential expression of
marker genes panels that include well-characterised cancer-associated factors such as
CDH1 (epithelial cadherin; E-cadherin), 5HT2B (5-hydroxytryptamine (serotonin)
receptor 2B) and EIF1B (eukaryotic translation initiation factor 1B) (Harbour et al.,
2013). Although distinct biomarker profiles have been validated for personalised patient
management, invasive surgical procedures with significant risk of sight threatening
complications are required in order to obtain sufficient tumour tissue for molecular
analysis (Pereira et al., 2013). Routine implementation of less invasive strategies would
enable early detection of metastasis and/or implementation of pre-emptive treatment
strategies.
Given that metastasis in UM arises from haematogenous dissemination, investigation of
circulating tumour cells (CTCs) and circulating tumour DNA (ctDNA) could provide a
unique opportunity for genetic analysis of the patient’s tumour through a simple and safe
blood test. The high proportion of recurrent hot spot mutations in GNAQ and GNA11
allows the detection of ctDNA in UM by droplet digital PCR (Versluis et al., 2015).
Bidard et al. (2014), detected ctDNA in 84% UM patients with metastatic disease, with
ctDNA levels correlating with miliary hepatic metastasis, metastasis volume and number
of CTCs. Detectable ctDNA correlated with a poor prognosis (Bidard et al., 2014).
However, the presence of ctDNA is yet to be evaluated in patients with localised UM. On
the other hand, circulating tumour cells (CTCs) have been previously detected early stage
UM (Suesskind et al., 2011; Ulmer et al., 2008). CTCs have shown to constitute a source
of tumour DNA that reflects the genetic landscape of the primary tumour (Gasch et al.,
2013; Heitzer et al., 2013a; Maheswaran et al., 2008). Thus, it would be possible that
CTCs can be used to detect tumour specific mutations and chromosomal copy number
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variations that predict the risk of metastasis for individual UM patients. To achieve this,
CTCs need to be efficiently isolated in early stage UM cases.
Current methods for isolating UM CTCs involve immunomagnetic capture and size based
filtration, however the well-documented heterogeneous nature of UM cells is likely to
complicate the successful isolation of CTCs from all patients. Immunomagnetic capture
of UM CTCs by targeting the melanoma-associated chondroitin sulphate proteoglycan
(MCSP (also known as CSPG4, NG2)) protein was shown to successfully detect CTCs in
patients with primary disease, detecting CTCs in 19% (1-5 CTCs, median = 2.5 CTCs,
per 50 mL of whole blood) (Ulmer et al., 2008) and 14% (1-8 CTCs, median = 1, per 50
mL of whole blood) of patients (Suesskind et al., 2011). Bidard et al. detected UM CTCs
in only 30% of patients with metastatic disease using the CellSearch system (Janssen
Diagnostics) which targets the melanoma marker MCAM (melanoma cell adhesion
molecule) and stains for MCSP (Bidard et al., 2014). However, a method using dual
marker enrichment protocol targeting CD63 (NKI/C3) and glycoprotein 100 (gp100,
NKI/BETEB), allowed for the detection of CTCs in 94% of patients with primary UM
(Tura et al., 2014). Thus, a multi-marker approach may be key to enriching the capture of
CTCs from the majority, if not all, UM patients. In fact, our previous study in metastatic
melanoma showed that targeting multiple melanoma specific membrane proteins resulted
in the enrichment of a larger number of CTCs (Freeman et al., 2012).
Here we initially evaluated the blood of primary UM patients for both: the number of
CTCs immunomagnetically captured using a single marker (MCSP) and the level of
plasma ctDNA. To enable greater efficacy and accuracy of capture of CTCs from UM
patients, we then systematically analysed the expression of several markers in a primary
UM tumour microarray and in five UM cell lines. Furthermore, we tested these markers
alone and in combination for their capacity to immunomagnetically capture UM cells
spiked into peripheral blood.
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Materials and Methods
Patients
UM patients from the Lions Eye Institute and Royal Perth Hospital, Perth, Western
Australia were enrolled in the study between March 2014 and August 2016. UM was
diagnosed by clinical and ultrasound examination performed by a specialist
ophthalmologist to evaluate the size and location of the intraocular tumour including the
presence of ciliary body involvement. Written informed consent was obtained from all
patients under approved Human Research Ethics Committee protocols from Edith Cowan
University (No. 11543) and Sir Charles Gardner Hospital (No. 2013-246), Western
Australia. Peripheral blood samples were taken prior to radiation plaque insertion or
enucleation. For CTC quantification, blood was collected in Vacutainer K2 EDTA tubes
(BD Biosciences), stored at 4°C, and processed within 24 hours. Plasma was isolated by
double centrifugation at 1600g for 10 min and stored at -80°C.
Antibody-Bead Coupling
Antibodies (BD Biosciences, Table S1) were covalently bound to magnetic beads using
a Dynabead Antibody Coupling Kit (Invitrogen) following manufacturer’s instructions.
10µg of antibody was used per mg of Dynabeads.
Circulating Tumour Cell Capture and Quantification
Peripheral blood mononuclear cells (PBMCs) were isolated from blood by density
gradient centrifugation over Ficoll-Paque (GE Healthcare) and resuspended in 1mL
MACS buffer (0.5% bovine serum albumin (BSA), 2mM EDTA in PBS, pH 7.2) prior to
the addition of 5µL of MCSP coated immunomagnetic beads. Cells and beads were
incubated at 4°C for one hour with rotation. Using a DynaMag-2 magnet (Life
Technologies), bead-captured cells were washed 3 times with MACS buffer, and then
fixed with 4% paraformaldehyde for 10 minutes at room temperature (RT). Cells were
washed once in PBS, incubated in PBS containing 10% normal donkey serum (NDS), 1%
BSA, and 0.2% Triton-X100 (TX-100) for 15 minutes then incubated for 1 hour at RT
with anti-MART1/gp100/S100β and with anti-CD45-PE antibodies diluted in PBS/1%
NDS/1% BSA/0.1% TX-100. After incubation, cells were washed in PBS/1% BSA/0.1%
TX-100, and incubated in 1:500 donkey anti-rabbit Alexa Fluor IgG 488 (Abcam) for 30
minutes at RT and placed on a magnet for 2 minutes. The resulting pellets were washed
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3 times with PBS/1%BSA/0.1%TX-100, resuspended in PBS, then mounted using
Prolong Gold Anti-Fade reagent with DAPI (Life Technologies). Slides were stored at
4°C, visualised and scanned using the Eclipse Ti-E inverted fluorescent microscope
(Nikon®). Stained cells were analysed using the NIS-Elements Analysis software,
version 4.2 (Nikon®, Japan). CTCs were defined as nucleated cells (DAPI positive) that
were positively stained for gp100, MART1 and S100β, and negatively stained for CD45.
Circulating Tumour DNA Quantification
Cell free DNA (cfDNA) was extracted from 1-5 mL of plasma using a QIAamp
Circulating Nucleic Acid kit (Qiagen) according to the manufacturer’s instructions and
stored at -80°C. ctDNA was quantified using droplet digital PCR using PrimePCR ddPCR
Mutation Assays (BioRad) for GNAQ Q209L and GNA11 Q209L. These assays are also
able to detect GNAQ/GNA11 Q209P mutations (Versluis et al., 2015). Droplets were
generated using an Automated Droplet Generator (BioRad), amplified using a C1000
Touch Thermal Cycler (BioRad) and analysed using a QX200 system (Bio-Rad). A
mutation-positive control, a healthy (wild-type) control and a no template control were
included in each run. QuantaSoft version 1.6.6 analysis software (Bio-Rad) was used for
data acquisition and analysis. Only tests providing more than 10,000 droplets were used
for analysis. The number of copies of mutated DNA per 20 µL reaction was extrapolated
to calculate copies per mL. Samples derived from the plasma of healthy individuals were
used to determine the specificity of each assay (Table S2).
UM Specimens and Tissue Microarray Construction
Formalin-fixed, paraffin-embedded (FFPE) blocks from 10 primary choroidal UM treated
by enucleation between 2012 -2014 at Royal Perth Hospital, Western Australia, were used
to construct the tissue microarray (TMA). A waiver of consent was obtained for all
archived tissue blocks under approved Human Research Ethics Committee protocols from
Edith Cowan University (No. 12593), Western Australia. The TMA was generated using
the TMA Master Tissue Microarrayer (3DHistech). Duplicate (8 patients) and
quadruplicate (2 patients) 1 mm cores were taken from areas with high tumour content
designated by a pathologist. Non-UM control tissues were obtained from FFPE cutaneous
melanoma and normal tonsil, liver, lung, breast, and skin.
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Multiplex Ligation-Dependant Probe Amplification for Detection of Copy Number
Variants
To determine chromosomal copy number variations (CNVs), DNA was extracted from
FFPE UM specimens by proteinase K digestion and purification through spin columns
(Qiagen). For MLPA analysis, 50-120ng DNA was analysed using a SALSA P027-C1
UM probemix kit according to the manufacturer’s instructions (MRC Holland,
Amsterdam, Netherlands). Samples were separated by capillary electrophoresis on an
ABI-3730XL DNA Analyzer (Applied Biosystems) and analysed using Coffalyser
software (MRC Holland) to determine copy number changes on chromosomes 1p, 3, 6
and 8.
Immunohistochemistry
Immunohistochemistry was performed on 4 µm sections cut from the FFPE TMA block.
Sections were depariffinised in xylene followed by rehydration in graded ethanols for 3
minutes each then washed in running dH2O for 1 minute. Antigen retrieval was performed
in an 850W microwave oven for 15 minutes on 100% power in sodium citrate pH 6.0
buffer (gp100, MART1) or EDTA pH 8.0 buffer (MCAM, Nestin, ABCB5, RANK,
5HT2B, S100β, MCSP). Slides were then cooled for 8 minutes in running dH2O,
permeabilised in 0.025% TX-100 in TBS (50 mM Tris-Cl, 150 mM NaCl, pH 7.6) for 20
minutes then immunostained using an EnVision+ Dual Link System-HRP (DAB+)
(Dako) according to the manufacturer’s instructions. Briefly, slides were incubated with
Endogenous Enzyme Block for 10 minutes, rinsed 3 times for 5 minutes in TBS/0.025%
TX-100 then incubated overnight at 4°C with primary antibody diluted in TBS/1% BSA
(Table S1). The following day, slides were washed 5 times for 5 minutes in TBS/0.025%
TX-100, incubated with Labelled Polymer-HRP for 30 minutes, rinsed 3 times for 5
minutes in TBS/0.025% TX-100, incubated for 5 minutes with Substrate Chromogen, and
then rinsed in dH2O. Slides were counterstained with Harris hematoxylin (Sigma) for 8
minutes, rinsed in running dH2O for 1 minute, blued in 0.2% ammonia water for 2 minutes
and mounted with ProLong Gold Antifade Mountant (Thermo Fisher Scientific).
Immunostaining for each marker was evaluated by two independent observers as follows:
negative (0), weak (1), moderate (2) or strong (3).
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Cell lines
The cell lines MM28, MP38, MP46, MP65 and MP41 exhibiting genetic profiles typical
of clinical UM were kindly donated by Prof Roman-Roman from the Institut Curie,
France (Amirouchene-Angelozzi et al., 2014). Cells were cultured in RPMI 1640 medium
supplemented with 20% foetal bovine serum (FBS) at 37°C in a humidified 5% CO2
incubator.
Flow Cytometry
MM28, MP38, MP41, MP46, and MP65 cells were harvested by incubation in 5mM
EDTA in RPMI 1640, resuspended then washed 3 times in FACS buffer (PBS with 0.1%
BSA, 25mM HEPES, 1mM EDTA, pH 7.0), incubated with primary antibody (Table S1)
for 30 minutes at 4°C and washed 3 times in FACS buffer. Cells were then incubated with
secondary antibody Alexa Fluor 488 conjugated donkey anti-rabbit or anti-mouse Ig
(Abcam) diluted 1:500 in FACS buffer for 15 minutes at RT and washed 3 times in FACS
buffer prior to flow cytometric analysis on a Gallios Flow Cytometer (Beckman Coulter)
and analysed with the Kaluza software package (Beckman Coulter).
Immunocytochemistry
UM cell lines were fixed in PBS/4% paraformaldehyde for 10 minutes, washed 3 times
for 5 minutes in PBS, blocked in PBS/1% BSA/10% NDS, then incubated overnight at
4°C with primary antibody (Table S1) diluted in PBS/1% BSA/1% NDS and washed 5
times for 5 minutes in PBS. Cells were then incubated for 1 hour at RT with Alexa Fluor
488 conjugated donkey anti-rabbit or anti-mouse IgG (Abcam, Table S1) diluted 1:500
in PBS/1% BSA/1% NDS, washed 3 times for 5 minutes in PBS, mounted with ProLong
Gold Antifade Mountant plus DAPI (Thermo Fisher Scientific) and analysed using an
Olympus BX51 microscope equipped with an Olympus DP71 camera and DP Manager
Software.
Retrieval of UM Cells Spiked into Peripheral Blood Mononuclear Cells
UM cell lines were labelled with 2 µM CellTracker Red CMTPX Dye (Life
Technologies) by incubation at 37°C for 30 mins and harvested using 5 mM EDTA/RPMI
1640 (Gibco). Only cells with more than 90% viability were used. Following harvesting,
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50 cells (BETEB, MCAM, and MCSP) were manually captured and spiked into PBMCs,
equivalent to 4 mL blood, resuspended in MACS buffer. For 5HT2B and ABCB5 capture
1000 cells were spiked by dilution. 1 µL of antibody-bead conjugate was added to the
cells and incubated for 1 hour at 4°C with gentle rotation. Enriched cells were then placed
on a DynaMag-2 magnet (Invitrogen), washed 3 times with MACS buffer, fixed in 4%
PFA/PBS, washed once in PBS, and mounted using Prolong Gold with DAPI Antifade
Mounting Medium (Invitrogen). Slides were left for 24 hrs before scanning the entire area
for DAPI/CMTPX positivity. Cells that had a blue labelled nucleus, with red cytoplasm
were determined to be spiked UM cells whereas blue labelled nuclei without red
cytoplasm were classified as WBCs.

Results
Quantification of Circulating Tumour DNA (ctDNA) and Circulating Tumour Cells
(CTCs) in Patients with Localised UM Patients
To determine whether ctDNA was detectable in patients with localised UM, plasma
samples from 27 patients (clinical characteristics detailed in Table 1) were analysed for
the presence of the UM associated mutations GNAQ Q209L/P and GNA11 Q209L/P. We
did not gain previous knowledge of the mutational status of patient matched tumours.
Instead all patient bloods were tested for these mutations as they have been reported to
occur in approximately 77% of UMs (van Raamsdonk et al., 2010). We detected ctDNA
in 5 of the 27 patients tested (19%, range 2-28.5 copies), 2 cases had a GNAQ Q209L
mutation and 3 had the GNA11 Q209L variant. Of note, all five cases with detectable
ctDNA also had CTCs (Figure 1b). On those with detectable mutations, ctDNA levels
were associated with tumour size (largest basal/apical diameter) (Figure 1c and d).
To determine the UM CTC detection rate using a single target, CTCs were isolated from
blood samples donated by 23 UM patients using immunomagnetic capture targeting
MCSP. True CTCs were identified in this population by positive staining for
MART1/gp100/S100β and negative staining for CD45 (Figure 1a). A total of 15 (65%)
individuals had at least 1 CTC in 8 mL of blood, with a range of 1-37 CTCs detected,
while 12 (52%) patients had 2 or more detectable CTCs. Only single cells, rather than
clusters, were detected in all cases. The presence or quantity of CTCs captured using
MCSP did not correlate with the tumour basal or apical size (Figure e and f). Among
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the 10 cases that underwent tumour biopsy no significant difference was found between
the number of CTCs and monosomy or loss of chromosome 3 in the tumour (Figure 1g).
Analysis of Marker Expression in primary UM tumours
Due to our moderate rate of CTC capture in patients with a single marker, MCSP, we
performed a literature search to determine potential cell surface markers that could be
used in combination to improve the detection rate and the number of CTCs captured and
intracellular markers that could improve CTC identification.
The markers chosen included previously described targets for immunocapture or
identification of UM CTCs, such MCAM (Bidard et al., 2014), glycoprotein 100 (gp100)
(Hoashi et al., 2005; Tura et al., 2014; Tura et al., 2016), melanoma antigen recognised
by T cells 1 (MART1) (Zhang et al., 2013), and S100 calcium binding protein β (S100β)
(Harpio and Einarsson, 2004). Other molecules selected included 5-hydroxytryptamine
receptor 2B (5HT2B), a membrane protein previously shown to be upregulated in class
II UMs (high metastatic risk) (Onken et al., 2004) and liver metastasis (Zhang et al.,
2014). ATP-binding cassette sub-family B member 5 (ABCB5) previously found to be
enriched in cutaneous melanoma CTCs (Gray et al., 2015a; Schatton et al., 2008), and
reported to be localised at the leading edge of UMs (Thill et al., 2011), receptor activator
of nuclear factor κ β (RANK), which is involved in migration and metastasis of cutaneous
melanoma (Kupas et al., 2011) and found in cutaneous melanoma CTCs (Gray et al.,
2015a), and Nestin, a cancer stem cell marker (Neradil and Veselska, 2015), found
primarily in non-pigmented cells in UM (Thill et al., 2011), were also assessed for
expression in UM tumour tissue.
Marker expression was assessed in a tumour microarray (detailed clinical characteristics
Table 2) according to the intensity of immunohistochemistry staining (Figure 2a and b).
All tumour cores were assessable, with the exception of tumour specimen PUM7, where
only 3 of 4 cores could be scored. Representative images of positively stained cores for
each of the markers are shown (Figure 2c). Duplicate cores were generally consistent in
their staining intensity and the average intensity score per protein was calculated relative
to the mean intensity score of all tumours that expressed the protein. For most cases,
where strong staining for an individual marker was observed, that marker was
homogeneously expressed in the tumour (Figure 2c). An exception was S100β where
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only a proportion of tumour cells exhibited strong expression, with positively stained cells
often clustered in small areas (Figure 2c). All tumours expressed gp100 and MART1,
with an average expression intensity of 1.4±0.4 and 2.5±0.7 respectively (Table 3). Other
intracellular markers, S100β and Nestin were expressed at similar intensity but in a lower
proportion of tumours (70% and 60%, respectively). Interestingly, ABCB5 was strongly
expressed in 90% of tumours (average expression intensity 2.7±0.5). Of note, in addition
to its well-characterised membranous location (Lutz et al., 2016), ABCB5 was also
localised within the cytoplasm of UM cells (Figure 2c). Other markers such as 5HT2B
(1.1±0.2), MCAM (1.6±0.5) and RANK (1.3±0.4) exhibited moderate levels of
predominantly membrane-associated expression and were expressed in a lower
proportion of tumour samples (Table 3). Interestingly, 5HT2B and MCAM expression
coincide in various tumours (PUM5, 6, 10 and 9) and within areas of the tumours (Figure
2c). Lastly, MCSP was not detected in any of the UM specimens, but was strongly
expressed in the cutaneous melanomas used as positive controls (Figure 2a).
Analysis of Marker Expression in Primary and Metastatic Cell Lines
We further evaluated the expression of marker proteins in cell lines derived from primary
(MP38, MP41, MP46, and MP65) and metastatic (MM28) UM using flow cytometry and
immunocytochemistry. Flow cytometric analysis of UM cell lines revealed high levels of
expression of cell surface gp100 (BETEB), MCAM and MCSP, with differential marker
expression between cell lines (Figure 3). For example, MCSP, a biomarker commonly
used to capture CTCs was expressed in all cell lines except for MP41. In contrast, 5HT2B
and ABCB5 were expressed in only a small proportion of the cells within each cell line,
apart from MP38, which exhibited low but homogeneous staining for 5HT2B (Figure 3).
We also assessed, by immunocytochemistry, the expression of intracellular markers
which can be used for identification of CTCs and found that the melanocyte markers
gp100 and MART1 were uniformly expressed in all cell lines. Nestin and S100β were
expressed in a more heterogeneous pattern, with Nestin exhibiting high expression in
MM28, MP38, and MP41 whilst MP46 and MP65 had medium levels of expression, and
S100β only expressed in a subset of cells in each cell line (Figure 4).
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Immunomagnetic Isolation of UM Cell Lines
To determine if 5HT2B, ABCB5, gp100 (BETEB), MCAM, and MCSP were suitable for
capturing UM CTCs, we spiked cells into the equivalent of 4 mL of isolated PBMCs. We
found that immunomagnetic capture and enrichment of UM cells using individual
markers could capture large proportion of the spiked cells; BETEB 32±2/50 (64%);
MCAM (51%) and MCSP 33±3/50 (66%) (Figure 5). However, targeting 5HT2B and
ABCB5 captured a very low per cent of spiked cells 5HT2B 5±1/1000 (0.5%); ABCB5
3.6±0.5/1000 (0.36%), consistent with the low frequency of positive cells for these
markers (Figure 3). When all beads were combined a similar level of cell retrieval
59±9.5/100 (59%) was found when compared to individual beads targeting MCAM,
BETEB or MCSP (Figure 5).

Discussion
Prognostication and routine monitoring of UM patients constitute essential components
of disease management that are hampered by the limited availability of primary tumour
tissue, resulting from the preferred use of brachytherapy with sight-conserving surgery,
and a lack of sensitive validated tests to detect minimal residual disease or early disease
recurrence. As up to 50% of UM patients will develop metastatic tumours following short
or very long latency periods (Kujala et al., 2003), the ongoing monitoring of patients
should ideally involve relatively non-invasive procedures that minimise the high
cumulative radiation exposure associated with repeated scans. Analysis of CTCs, both to
stratify UMs into low or high risk categories and to monitor disease recurrence or
progression potentially fulfils these criteria, pending the development of robust CTC
capture and test methods.
As shown in this study, ctDNA is not commonly detectable in blood of patients with
localised UM. In contrast, most metastatic UM cases we have tested have detectable
ctDNA (data not shown), consistent with the report by Bidard et al. (Bidard et al., 2014).
Thus, ctDNA monitoring using sensitive methodologies like ddPCR might be useful for
early detection of metastatic disease. In addition to GNAQ and GNA11 mutations, other
‘hotspot’ mutations have been identified in primary UM, such as PLCβ4 D630Y (7%)
and CYSLTR L129Q (3%) (Johansson et al., 2016; Moore et al., 2016). The inclusion of
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assays to test for these mutations would increase the utility of ctDNA for monitoring of
disease burden.
To enrich for CTCs, a single marker has been used in patients with UM and this has
typically resulted in low numbers of patients having detectable CTCs. Previous reports
using MCSP to capture CTCs attained a detection rate of 14-19% in UM patients with
non-metastatic disease, with 1-5 CTCs detected in 50 mL of blood (Suesskind et al., 2011;
Ulmer et al., 2008). Although when we used the same single marker (MCSP) to capture
CTCs, our method of immunomagnetic isolation achieved a slightly higher detection rate
than previous reports, with 1-37 CTCs detected in 65% of cases, a result that may be
accounted for by differences in the isolation and detection methods employed, such as
immunostaining with multiple well expressed melanoma markers, and direct conjugation
of antibodies to immunomagnetic beads. In other studies, that used different markers to
capture CTCs, diverse rates of detection have been reported. For example, a study using
CellSearch (MCAM based capture) achieved a detection rate of 50% in patients with
non-metastatic disease, with 1-3 CTCs detected in 7.5 mL of blood (Bande et al., 2015).
More recently, Tura et al., (2014) showed that by targeting multiple markers NKI/C3 and
NKI/BETEB (CD63 and gp100) a CTC capture rate of 94% was able to be achieved in
patients with non-metastatic disease, with 1-10 CTCs detected in 10 ml of blood.
Consistent with these results, our laboratory has previously shown that a multi-marker
immunomagnetic enrichment protocol captured a higher number of cutaneous melanoma
CTCs by targeting four markers (Freeman et al., 2012).
To investigate potential markers for use for CTC capture, a panel comprising, 5HT2B,
ABCB5, surface-gp100 (BETEB), MCAM, and MCSP was chosen based on the known
roles of these factors in UM (Bande et al., 2015; Harbour and Chen, 2013; Thill et al.,
2011; Tura et al., 2014; Ulmer et al., 2008). Surprisingly, MCSP, which we and others
have successfully used to capture CTCs, was not expressed in any of the primary human
UM tumour specimens although it was strongly expressed in all but one of the UM cell
lines. Similar results of MCSP variable expression have been previously reported on other
UM cell lines (Cools-Lartigue et al., 2008). MCSP is highly expressed in cutaneous
melanomas, and although its expression is not well-characterised in UM, a previous study
has described its expression in approximately 95% (18/19) of primary UM tumours
(Campoli et al., 2004; Li et al., 2003). Reasons for the apparent lack of concordance
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between MCSP immunohistochemistry results and both our successful use of MCSP
antibodies to capture UM CTCs and the previous report of Li et al. (2003) are unknown.
However, it is interesting to note that the MCSP antibody clone (9.2.27) used in our CTC
capture protocol and in the study of Li et al (2003) were identical and differed from the
antibody clone used for immunohistochemical detection of MCSP. Another explanation
for our lack of apparent immunostaining of MCSP in our UM specimens may be due to
improper storage conditions or length of storage (Ramos-Vara et al., 2014; Xie et al.,
2011). It is unknown the specific effects of these conditions on MCSP. However, we
should note that other markers were positively stained in the same tumour samples.
Of the other markers tested, the well-characterised melanoma antigens, MART1 and
gp100 were expressed in all our UM tumours, supporting previous studies of their
detection in UM specimens and their potential inclusion in marker panels to capture UM
CTCs (de Vries et al., 1998). Similarly, S100β was widely expressed but in a lesser
proportion (70%) of our UM specimens, while MCAM, which was previously reported
to be expressed in all of a cohort of 35 specimens (Beutel et al., 2009), was expressed in
just 4 of our 10 UM specimens. TMAs provide a useful means to evaluate biomarker
expression, however the relatively small areas of tumour tissue that are able to be
evaluated in 1mm cores, may result in underestimation of antigen expression if the
immunohistochemical staining pattern is heterogeneous. For example, heterogeneous
MCAM expression in UM described in a previous report (Beutel et al., 2009) may have
contributed to the lower proportion of MCAM-expressing tumours identified in the
present study.
A previous study has shown that 5HT2B expression is strongly associated with class II
UM (Onken et al., 2010) and that its expression is significantly upregulated in UM liver
metastases (Zhang et al., 2014). Although the role of 5HT2B in metastatic progression of
UM or promotion of metastatic tumour growth is unknown, inclusion of 5HT2B in
biomarker panels for CTC isolation may facilitate capture of class II UM cells.
An interesting finding was that ABCB5 was expressed at elevated levels in a high
proportion (90%) of UM specimens in a predominantly cytoplasmic localisation. This
contrasts with the sporadic expression of ABCB5 in cutaneous melanoma tumours (Frank
et al., 2005; Gray et al., 2015a). ABCB5, is a cancer stem cell marker (Schatton et al.,
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2008) over-expressed in cutaneous melanoma CTCs (Gray et al., 2015a; Ma et al., 2010).
As class II UM significantly correlates with the gene expression profiles of primitive
ectodermal and neural stem cells (Chang et al., 2008), use of ABCB5 in biomarker panels
to detect UM CTCs may select for cells with an increased propensity for metastasis
development.
Biomarker expression was also examined in UM cell lines, which carry chromosomal
losses and gains typical of human UM specimens (Aalto et al., 2001; Damato et al., 2010).
Several of the markers, notably MCAM, MCSP and gp100 (BETEB) were expressed in
most UM cell lines and in the large majority of cells in those cell lines. On the other hand,
5HT2B and ABCB5, which was highly expressed in human UM tissue, was weakly and
sporadically expressed in the UM cell lines analysed. Discordance on antigen expression
between tumour tissue and cell lines could be attributed to environmental differences, and
selection or adaptation to in vitro growing conditions (Kamalidehghan et al., 2012).
5HT2B, ABCB5, surface gp100 (BETEB), MCAM, and MCSP were also tested for their
ability to isolate spiked UM cell line cells into PBMCs. We found that BETEB, MCAM,
and MCSP individually retrieved ~60% of UM of spiked cells, while 5HT2B and ABCB5
only managed to retrieve an extremely low number (>1%) of cells. This may be due to a
combination of factors such as low expression level on UM cells or the affinity of
antibodies used. However, both markers, although capturing only a small fraction of the
spiked cells, had little non-specific binding to PBMCs. When each marker was combined,
the retrieval rate was similar to the capture rates of BETEB, MCAM, and MCSP
individually, which may indicate that as cell lines express high levels of each marker, the
difference in binding capacity is minimal. The benefit of multiple markers is targeting the
wide phenotypic differences in patients, where if for example, a patient lacks MCSP
expression then the remaining markers will continue to ensure CTCs are isolated in these
patients. Future studies will determine the detection rate yield by using this marker
combination to capture CTCs in localised UM patients.
Previous reports have identified that the numbers of CTCs found in patients with localised
UM do not appear to correlate with prognosis or survival outcomes (Suesskind et al.,
2011; Tura et al., 2014). Similarly, CTC numbers did not correlate with known tissue
prognostic markers, such as monosomy of chromosome 3 and tumour size in the small
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number of cases in the present study. Therefore, our aim is not to enumerate CTCs as
prognostic marker, but to capture CTCs in most patients to provide sufficient cells to
analyse the genetics of the parental tumour. CTCs as a liquid biopsy may present an
alternative source of tumour genetic material able to be used to investigate markers of
patient prognosis, and therefore attempting to capture CTCs in almost all patients is
worthy of investigation. In this regard, CTCs have been shown to constitute a source of
tumour genetic material which represents that within the primary tumour (Heitzer et al.,
2013a). Tura et al. (2016) showed that chromosome 3 loss, a marker of poor prognosis
could be determined by fluorescence in-situ hybridization in single CTCs and that these
results matched the primary tumour in 10/11 cases.
In summary, the inaccessibility of primary UM and the strong likelihood of metastatic
progression of the disease following only local control of tumours, presents major
challenges for pathology in the provision of prognostic marker profiles and for monitoring
of progression of the disease. These issues may be overcome using liquid biopsies to
analyse CTCs and ctDNA, however optimisation of methods will be required to allow
findings to be translated into clinical practice. A necessary first step in this process is the
determination and characterisation of biomarker panels for CTC recognition, with the
present study identifying membrane biomarkers that are widely expressed in UM and
which may be combined to maximize CTC capture in UM patients.
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Table 1: Clinical, Genotypic, and Histological Characteristics of Patients
Undergoing Circulating Tumour Cell Capture
Patient
Number

Age
(yrs)

185
187

Genetic
Features

Tumour
Size
(Apex)
(mm)

Largest
Basal
Tumour
Diameter
(mm)

Eye

Location

Cell
Morphology
(Callendar
Classification)

-

Left

Choroid

Spindle

Monosomy 3

8.3

10

-

Right

Choroid

-

-

15

20

0

-

Right

Choroid

-

Monosomy 3

2.5

8

2

0

-

Left

Choroid

-

Disomy 3

4

12

3

0

-

Right

Ciliary
Body

-

-

12.5

18

Normal
chromosome
1p; disomy 3;
borderline
loss 6p;
borderline
loss 8

6

10

11.8

Sex
(M/F)

CTC
Count

ctDNA
Copies

ctDNA
Mutation

70

F

0

0

78

M

1

0

198

54

F

-

211

52

F

210

57

M

GNAQ
Q209L

Right

Choroid

-

0

-

Right

Choroid

-

-

3.7

Left

Choroid

-

Monosomy 3;
L8q

11

17

Left

Choroid

-

-

4

10.7
12.9

212

59

M

37

6

214

52

M

1

220

64

M

5

28.5

GNA11
Q209L

243

74

F

-

0

-

242

59

F

4

6

GNAQ
Q209L

Left

Choroid

-

-

7

263

57

F

0

0

-

Right

Choroid

Spindle B

L3; G6p; G6q

10.5

9

312

50

F

22

0

-

Right

Choroid

Spindle B

-

12

12

316

57

M

10

0

-

Right

Choroid

-

-

2.8

7

317

64

M

1

2.2

GNA11
Q209L

Left

Choroid

-

-

7.6

5.9

Choroid

-

Normal
chromosome
1p; disomy 3;
gain in 6p;
gain in 8q

2.5

10

12

322

48

F

8

0

-

Left

321

61

M

0

0

-

Right

Choroid

Spindle B

-

6.6

340

62

F

2

0

-

Right

Choroid

-

-

5.6

8

354

43

F

6

0

-

Right

Choroid

-

-

4.5

10

385

74

F

0

0

-

Left

Choroid

Mixed

L1p;
Monosomy 3;
G8q

4

20

386

63

M

0

0

-

Right

Choroid

-

-

6.4

11.5

400

62

F

0

0

-

Left

Choroid

-

Disomy 3

4.87

8

413

63

M

-

0

-

Left

Ciliary
Body

Spindle B

Monosomy 3

9.8

15

414

51

F

0

0

-

Right

Choroid

-

-

2.8

8

445

35

M

7

2

GNA11
Q209L

Right

Choroid

-

Disomy 3

2

5

451

79

F

2

0

-

Right

Choroid

-

-

3.8

8.5

481

74

M

-

0

-

Left

Choroid

-

-

9.2

13

Spindle

Unclassifiable
3p with a
normal 3q;
G6p.

6.5

12

503

64

M

0

0

-

Right

Choroid

Dash (-) where data was unavailable.
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Table 2: Clinical, Genotypic, and Histological Characteristics of Patient Tissue Samples Used on the Tissue Micro Array
ID

Age
*

Cell
Morphology
(Callender)
Mixed
(Predominantly
spindle)

TMA Cell
Morphology
(Callender)

Tumour Size
Basal x Height

Location

Metastatic
Disease: Interval
Time (Months)

MLPA

PUM1

38

Mixed

12 x 9 mm

Left choroidal

No: 51

No convincing evidence of chromosomal loss or gain**

PUM2

51

Mixed

Spindle / Mixed

12 x 8 mm

Right choroidal

Yes: 18

loss 3p, 3q, gain 8q

PUM3

65

Mixed

Epithelioid /
Mixed

10 x 6 mm

Left choroidal

Yes: 33

loss 3p, gain 8q

PUM4

47

Mixed

Epithelioid /
Mixed

11 x 12 mm

Right choroidal

Yes: -3

loss 3p, 3q, gain 8q

PUM5

59

Mixed

Spindle / Mixed

9 x 4 mm

Right choroidal

No: 42

8q gain

PUM6

31

Mixed
(epithelioid
cells <10%)

Epithelioid /
Mixed

15 x 12 mm

Left choroidal

Yes: 12

8q gain, some evidence of 3p loss, but not strong

PUM7

42

Spindle B

Spindle

16 x 9 mm

Left choroidal

Unknown

No convincing evidence of chromosomal loss or gain

PUM8

80

Mixed

Spindle

11 x 12 mm

Left choroidal

Unknown

loss 1p, 3p, 3q, gain 8q

PUM9

59

Mixed

Epithelioid /
Mixed

14 x 8 mm

Right choroidal

Yes: 3

loss 3p, 3q, gain 8q

PUM10

79

Mixed

Epithelioid

20 x 15 mm

Right choroidal

No: 19

No convincing evidence of chromosomal loss or gain**

* Age at enucleation
** Poorer quality DNA
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Table 3: Average Marker Intensity Score
Average Marker Intensity Score
ABCB5

MART1

gp100

S100β

Nestin

5HT2B

MCAM

RANK

MCSP

PUM5

3

3

1

2

2

1

1.5

0

0

PUM6

3

1

2

1.5

0

1

1

0

0

PUM10

2

3

1

2

2

1

2

2

0

PUM9

2

2

1

0

2

1.5

2

1

0

PUM2

3

2.8

1

2

1.5

1

0

0

0

PUM3

3

2.5

2

1

2

0

0

1

0

PUM4

2

2.6

1.3

0

0

1

0

1.3

0

PUM8

3

3

1.5

0

0

0

0

1

0

PUM7

3

3

1

1

0

0

0

0

0

PUM1

0

2

2

1

0

0

0

0

0

ID

0 – not expressed, 1 – low expression, 2 – moderate expression, 3 – high expression
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Supplementary Table 2: Antibody Information
Antibody

Vendor

Product Code

5HT2B

Alomone

ASR-035

ABCB5

Abcam

ab140667

BETEB
gp100
MART1

Abcam
Abcam
Abcam

ab34165
ab137062
ab51061

MCAM
MCAM

N/A (donated)
BD
Biosciences
NOVUS
BD
Biosciences
Abcam
Abcam
Abcam
Abcam
Abcam
Abcam

ab13918
ab4066

Abcam

MCSP
MCSP
Nestin
RANK
S100
Rabbit Isotype
Mouse Isotype
Anti-Rabbit
AF488
Anti-Mouse
AF488

Use
IHC, ICC,
FACS
IHC, ICC,
FACS
ICC, FACS
IHC, ICC
IHC, ICC,
FACS

Dilution

CC9 (clone)
550314

IHC
ICC, FACS

1:20
1:100

NB100-2688
554275

IHC
ICC, FACS

1:100
1:100

ab18102

1:100

ab150065

IHC, ICC,
FACS
IHC
IHC, ICC
ICC, FACS
ICC, FACS
ICC, FACS

ab150065

ICC, FACS

1:500

ab172730
ab18437

1:400 (IHC & ICC);
1:100 (FACS)

1:100
1:10
1:50
1:100 (ICC &
FACS) 1:1000
(IHC)

1:100
1:500
1:100
1:100
1:500

Immunohistochemistry (IHC), Immunocytochemistry (ICC), Flow Cytometry (FACS)
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Figure Legends
Figure 1: Circulating Tumour Cell and Circulating Tumour DNA Quantification in
Primary Uveal Melanoma. a) Example of a UM CTC found in patient blood. Green
fluorescence (AF488, Mel) indicates staining with a mix of antibodies against the
melanoma markers MART1, gp100 and S100β; red fluorescence (PE) indicates CD45
positivity and blue fluorescence (DAPI) indicates the presence of a nucleus. CTCs were
identified as green and blue positive and red negative cells. Graphs illustrate CTC count
vs b) basal median diameter (n=20) or c) tumour size as apical height (n=22). d)
Comparison of CTC counts in UM patients with and without monosomy in Chr3 (n=8).
e) Graphs illustrate ctDNA copies/mL vs CTC count in 8 mL of blood (n=23). Blue dots
indicate the presence of the GNAQ Q209L mutation and red dots indicate the GNA11
Q209L mutation. Graphs indicate ctDNA copies/mL vs f) basal median diameter (n=23)
or g) tumour size as apical height (n=25).
Figure 2: Immunohistochemistry of Uveal Melanoma. TMA staining demonstrating
a) Examples of how tumours were scored for protein localisation. Left shows strong
membranous staining and right shows strong cytoplasmic staining. Representative image
of positive MCSP membranous staining. b) Examples of the criteria used to measure
staining intensity, from 1 indicating weak staining to 3, the most intense staining. A tissue
staining negatively by immunohistochemistry (0), is also shown (left), with intrinsic
melanin pigment. c) Shows a typical positive staining pattern for each of the markers
analysed. Dark granular black spots are melanin deposits. All images taken at 200x
magnification. Scale Bar = 200 μM.
Figure 3: Expression of Markers in Cell Lines by Flow Cytometry. Flow cytometric
analysis of primary (MP38, MP41, MP46, and MP65) and metastatic (MM28) cell lines.
Grey profiles represent negative controls using either rabbit or mouse IgGs depending on
the primary antibody host
Figure 4: Immunocytochemical Analysis of Uveal Melanoma Cell Lines.
Intracellular markers and isotype controls. All images taken at 400x magnification.
Scale bar denoting 100 µm.
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Figure 5: Recovery of Spiked Uveal Melanoma Cells from the Mononuclear Blood
Cell Fraction. 50 cells were spiked into PBMC equivalent to 4 ml of blood. MP38 cells
were used to test beads conjugated to antibodies targeting 5HT2B, MP41 were used for
BETEB and MCAM, MP46 were used for ABCB5 and all beads, and MP65 cells were
used for MCSP. Data represent the mean ± SD of three independent experiments.
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Abstract
Metastatic risk can be easily defined by mutations in chromosomes 1, 3, 6, and 8 in uveal
melanoma (UM). Previous research has indicated that circulating tumour cells (CTCs)
are detectable in virtually all patients, irrespective of the propensity of their tumour to
metastasise. Herein we tested the ability to accurately determine copy number alterations
after isolation and detection of single CTCs. We found that immunomagnetic enrichment,
fixation, permeabilisation, and immunostaining caused no significant alteration to CNV
detected within single UM cells after whole genome amplification using PicoPlex whole
genome amplification kit followed by low-pass whole genome sequencing (WGS) using
the Ion Torrent PGM system. Once optimised, we validated then used this protocol to
detect a gain of chromosome 8 in a single patient with UM, a classically poor prognostic
feature. Therefore, we show here that CTCs offer a non-invasive method to acquire
tumour genetic material with which to assess UM patient prognosis.
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Introduction
Uveal melanoma (UM) has a strong propensity to metastasize, with approximately 50%
of all patients developing incurable metastatic disease. Patients at a high metastatic risk
can be identified by genetic analysis of the primary tumour by gene expression analysis
(Onken et al., 2010), detection of distinct chromosomal copy number variations (CNV)
(Damato et al., 2010), or genetic mutations (Harbour and Chao, 2014).
Although powerful for determining patient metastatic potential and prognosis, these
molecular tools require the acquisition of tumour material from the eye which can lead to
several complications, including blindness (Pereira et al., 2013). Fortunately, there may
be another suitable source of tumour genetic material from which patient prognosis can
be derived. Circulating tumour cells (CTCs) are cells shed from a tumour and carried
around the body via the cardiovascular or lymphatic system. CTCs have previously been
shown to harbour similar genetic profiles to patient primary tumours (Heitzer et al.,
2013a), and can be used to detect tumour specific mutations in other cancers (Gasch et
al., 2013; Heitzer et al., 2013a; Maheswaran et al., 2008). In UM a single CTC has been
amplified and analysed by array comparative genomic hybridisation showing
abnormalities associated with poor prognosis in UM (Ulmer et al., 2004), and more
recently prognosis has been derived from CTCs in patients using a modified fluorescent
in-situ hybridisation technique to detect CNVs of chromosome 3. (Tura et al., 2016).
As the genotype of UM can predict the metastatic propensity of the primary tumour, the
detection and isolation of single CTCs may allow for an accessible and accurate method
of prognostication. However, there are several methodological hurdles that need to be
overcome to produce a cost-effective assay for whole genome CNV analysis. Firstly, the
processing of patient blood samples to isolate and detect patient CTCs may affect the
genetic material of the cell. Secondly, as single cells do not harbour enough DNA for any
meaningful genetic analysis they must undergo whole genome amplification which may
also lead to discrepancies in the analysis of the genetic profile of the cell. Herein we
assessed the effects of processing single UM cells (isolation, detection, capture, whole
genome amplification, and low-pass whole genome sequencing) to determine the viability
of CTCs as an alternative, less invasive method of accurately predicting patient prognosis.
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Materials and Methods
Cell Culture
The cell lines MP38, MP41, and MP65 exhibiting genetic profiles typical of clinical UM
were kindly donated by Prof Roman-Roman from the Institut Curie, France
(Amirouchene-Angelozzi et al., 2014). Cells were cultured in RPMI 1640 medium
supplemented with 20% foetal bovine serum (FBS), 100 units/mL Penicillin and 100
μg/mL Streptomycin (Gibco) at 37°C in a humidified 5% CO2 incubator.
Antibody-Bead Coupling
CD146 (MCAM, P1H12, BD Biosciences, 550314), melanoma associated chondroitin
sulphate (MCSP, 9.2.27, BD Biosciences, 554275), and surface gp100 (NKI/BETEB,
Abcam, ab34165) were covalently bound to magnetic beads using a Dynabead Antibody
Coupling Kit (Invitrogen) following manufacturer’s instructions. 10µg of antibody was
used per mg of Dynabeads.

Single Cell Isolation and Processing
Cell Line: UM cell line cells were incubated in serum-depleted media for 16-18 hours to
synchronise the cell cycle of all cells (Supplementary Figure 1), then at this point cells
were harvested using 5mM EDTA in RPMI 1640 media. Three cells were captured and
subjected to WGA. The rest of the cells were placed into 1 mL MACS buffer and 5 µL
Dyna-Beads coated with anti- CD146 antibody was added, followed by a 1 hr incubation
at 4°C on a roller. Cells were then placed on a magnet for 2 minutes, and washed with
magnetic activated cell sorting buffer (MACS, 0.5% BSA/2mM EDTA/PBS, pH 7.2) 3
times. Cells were resuspended in 4% paraformaldehyde in PBS for 10 minutes, placed on
a magnet for 2 minutes and washed in PBS 3 times. Three cells were captured at this point
and subjected to WGA. The rest of the cells were blocked and permeabilised using 3%
BSA/10% normal donkey serum/0.2% Triton-X 100/PBS for 15 minutes, washed once in
1% BSA/0.1% triton-X 100/PBS, and incubated with primary antibody (MART1, gp100,
S100, CD45) diluted in 1% BSA/0.1% triton-X 100/PBS for 1 hr, followed by incubation
with secondary antibody donkey anti-rabbit Alexa Fluor 488 (Abcam) and 10 µg/mL
Hoechst 33342 (Thermo Scientific) for 30 minutes. Cells were washed 3 times in PBS.
Cell suspension was placed on a glass microscope slide and analysed by fluorescent
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microscopy. Single cells were picked using the MMI CellEctor (Molecular Machines)
and placed into 0.2 mL PCR tubes (Eppendorf).
PBMC: Healthy donor blood was subjected to density gradient centrifugation via FicollPaque to separate peripheral blood mononuclear cells. After 3 washes in 50 mL PBS cells
were resuspended in 1mL PBS. Some cells were captured at this point and subjected to
WGA. The remainder of the cells were processed as described for the UM cell line
protocol above.
Whole Genome Amplification
Whole genome amplification (WGA) was performed using the PicoPlex WGA Kit
(Rubicon Genomics) and the Repli-G Single Cell Kit (Qiagen) to manufacturer’s
specifications following isolation of single cells. 1 ng of genomic DNA (gDNA) from a
healthy donor, and from MP38, MP41, and MP65 cell lines was also amplified. WGADNA was purified using the Qiaquick PCR Purification Kit (Qiagen) and quantified using
the Qubit dsDNA BR Assay Kit (Invitrogen). Whole Genome Amplified DNA was run
on the High Sensitivity D1000 ScreenTape Assay (Agilent) to ensure that the majority of
WGA product centred around 400bp in size. WGA-DNA was also subjected to multiplex
PCR covering 100, 200, 300, and 400bp amplicons in the GAPDH gene as described
previously (van Beers et al., 2006). WGA-DNA was regarded as high quality if the
majority of WGA-DNA fragments were approximately 400bp in size and the multiplex
PCR produced 4 amplicons.
Low-Pass Whole Genome Sequencing
One hundred nanograms of DNA was used to construct 200bp libraries made using the
Ion Xpress Plus Fragment Library Kit (Life Technologies) and barcoded using the Ion
Xpress Barcode Adapters 1-96 Kit (Life Technologies). Somatic mutations and CNVs
were analysed using the Ion Reporter software (Life Technologies).
Ethics and Patient Blood Samples
All procedures have been approved by Human Research Ethics Committees at Edith
Cowan University (No. 11543) and Sir Charles Gardner Hospital (No. 2013-246), and
Royal Perth Hospital, Western Australia. Patient blood samples were obtained from
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Royal Perth Hospital, Western Australia. The patient was diagnosed as per guidelines by
the American Joint Committee on Cancer. Patient blood samples were taken prior to
commencement of treatment. Blood was drawn by phlebotomists into BD Vacutainer K2
EDTA tubes (BD Biosciences) and processed within 4 hours.
Patient Sample Processing
The patient is a 59-year-old female diagnosed with choroidal UM. Peripheral blood was
drawn prior to radiation plaque therapy. After harvesting plasma, PBMCs were isolated
by density gradient centrifugation using Ficoll-Paque (GE Healthcare). Separated PBMCs
were resuspended in 1mL MACS buffer, and 2µL of Dyna-Beads coated with anti-surface
gp100, MCAM, and MCSP, was added. Cells were fixed in 4% paraformaldehyde and
immunostained as described above for UM cell lines, and analysed by fluorescent
microscopy. Cells that were green (MART1/gp100/S100β positive), not red (CD45
negative), and had a blue nucleus (Hoechst 33342) were deemed to be CTCs, and cells
that were red with blue nucleus were classified as PBMCs. Single CTCs and PBMCs were
captured using the MMI CellEctor (Molecular Machines) and deposited in 0.2 mL PCR
tubes in 2 µL volumes. Captured cells were whole genome amplified by PicoPlex and
sequenced as described above in Whole Genome Amplification and Sequencing.
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Results
We selected 3 UM cell lines with multiple chromosomal CNVs (Amirouchene-Angelozzi
et al., 2014), MP38, MP41, and MP65 to evaluate our methodology. Single cells were
picked and subjected to WGA, i) prior to any processing, ii) after fixation using
paraformaldehyde, and iii) after permeabilisation and immunostaining.
Quality Control of Whole Genome Amplified DNA
To ensure that the WGA produced high quality DNA suitable for accurate CNV analysis,
WGA-DNA was analysed using TapeStation and multiplex PCR. WGA-DNA was
determined to be suitable for low-pass WGS if the multiplex PCR produced 4 amplicons
(Figure 1a) and if the TapeStation showed the majority of WGA-DNA to be
approximately 400bp in length (Figure 1b).
Effects of the Whole Genome Amplification Process on Downstream Copy Number
Variants
Firstly, we wished to ascertain whether the WGA process itself led to any significant
biases during sequencing. We sequenced bulk gDNA, 1ng of gDNA subjected to WGA,
and 3 single cell WGA-DNA products. Here we showed that when compared to the bulk
gDNA, the gDNA-WGA (PicoPlex only) and single cell WGA-DNA from both PicoPlex
(Figure 2) and Repli-G (Figure 3) do not differ significantly. Small differences were
observed, e.g. the lack of a gain in 6p and 14p in MP38 cell 3 (Figure 2a), possibly due
to the stochastic effect of cell culture. However, Repli-G has more noticeable spread on
the copy number per bins within the chromosomes, reducing confidence in the CNV call.
For example, more CNV errors were observed in Repli-G MP41 Cell 2 than in any of the
PicoPlex analysed cells where the CNVs observed resembled the known values
(Amirouchene-Angelozzi et al., 2014). Therefore, the process of WGA by PicoPlex
introduced little bias at a WGS depth of 0.01-0.1x.
Effects of Cell Processing on Whole Genome Amplification and Copy Number
Variants
Next, we wanted to test the effects of processing of cells, for the identification of CTCs
in patients. To determine these effects, we analysed WGA-DNA of cells that had been
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fixed, or fixed, permeabilised, and stained using both Repli-G and PicoPlex WGA
methods. Repli-G did not amplify samples that had been fixed. Compared to the genomic
DNA (Figure 4a), fixation in 4% paraformaldehyde did not significantly alter the
PicoPlex WGA-DNA (Figure 4b). However, the full process of fixation,
permeabilisation, and staining did cause some alterations to the chromosomal CNV, such
as a gain in the entirety of chromosome 2 and variance in chromosome 12q, however
these cells continued to correctly display the correct prognostic information, concordant
with the gDNA alterations found in chromosomes 1, 6, and 8 (Figure 4b-d).
Copy Number Variations Detected in Patient Samples
To demonstrate the clinical application of the methodology described, we isolated CTCs
from a UM patient prior to radiation plaque insertion. We detected one CTC in this patient
and isolated this for further analysis. We found in a single CTC from this one patient
(Figure 5), a gain of chromosome 8, a regularly amplified chromosome in poor
prognostic UM.
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Discussion
The majority of UM CTC studies utilise detection and quantification of CTCs to try and
determine prognosis but have generally found no significance between the levels of CTCs
and patient prognosis (Suesskind et al., 2011; Tura et al., 2014). We have shown similar
results in our previous studies (not published). Approximately 50% of patients develop
metastasis, and most patients have CTCs irrespective of the propensity of their tumour to
metastasise, indicating the presence of CTCs is not the determining factor in the
production of metastasis. Therefore, the ability to detect the genomic features in these
CTCs may offer a greater perspective into patient metastatic risk and prognosis over
quantification of CTCs. This study illustrates that immunomagnetic capture and detection
of single UM cells followed by WGA and low-pass WGS (>0.01-0.1X) can accurately
represent the genomic landscape of the primary tumour.
The notable differences we found in UM cells that were immunomagnetically captured,
fixed, permeabilised, and stained prior to amplification with PicoPlex relative to known
chromosomal arrangements (Amirouchene-Angelozzi et al., 2014), may be partially
explained by the use of a later passage of MP41 compared to the initial experiments on
fresh cells, as single PBMCs consistently retain their balanced karyotype. Thus, PicoPlex
is a suitable choice of WGA that is able to retain the genetic profile of single cells, and is
suitable for detection of CNVs associated with prognosis in UM.
The critical step in the success of using single CTCs as a surrogate for primary tissue to
determine prognosis, is the choice of WGA kit. Previous studies have assessed the
limitations and benefits of many different kits (Gawad et al., 2016; Huang et al., 2015;
Zong et al., 2012), but we found that PicoPlex was able to amplify single cell derived
DNA with only minor alterations regardless of chemical fixation via covalent crosslinking. Moreover, PicoPlex has an intermediate false positive/negative and high
uniformity of coverage (Gawad et al., 2016), allowing for greater success in measuring
CNVs (de Bourcy et al., 2014).
PicoPlex, when compared to the multiple displacement amplification (MDA) method
such as Repli-G, produces small (~400bp) fragments. This prevents the use of some probe
based detection methods for downstream analysis such as ddPCR or Ampliseq kits to
detect somatic alterations in the amplified DNA as amplification sites may not be covered
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by previously designed primers whereas detection of SNPs relevant to UM was possible
in all successful cells amplified using the MDA method (Figure S2).
Due to the infrequent nature of fine-needle biopsies, comparison between the tumour and
CTC genotypes was not possible for the single patient assessed here. Future studies would
be required to confirm the relationship between genetic profile of the primary tumour and
disseminated CTCs. However, our single patient CTC displayed a gain of chromosome
8 which has been regarded as an early event in tumourigenesis of UM (Ehlers et al., 2008;
Hoglund et al., 2004), and may indicate the dissemination of CTCs is also an early event
of UM metastasis in this patient. Tura et al (2016) revealed significant concordance
between the status of chromosome 3 in the primary tumour and CTCs. Furthermore,
methods that employ WGA may be able to further stratify patients with class I tumour
phenotype into the more recently described class Ia or Ib owing to mutations that
generally segregate into these classes (Field et al., 2016) enabling a finer assessment of
patient metastatic propensity over the classical class I/II. Additionally, a small portion of
metastasising UM are disomy 3. WGA-DNA may be useful in determining mutations
associated with disomy 3 metastatic UM (Lake et al., 2010) or isodisomy 3 via allelic
frequency. However, this assessment was beyond the scope of this study.
Previous studies have used array comparative hybridization (Ulmer et al., 2004) or
fluorescence in-situ hybridisation (FISH) (Tura et al., 2016) to detect changes relevant to
patient prognosis. We utilised low-pass WGS due to its effectiveness in determining
chromosomal arm level alterations across the whole genome, whereas aCGH is expensive
and FISH is limited to a single or a couple of loci, and orientation of cells can cause underor overestimation of changes to CTC genomic profiles. Therefore, the use of low-pass
WGS as a method of predicting CNV alterations may be more beneficial due to its lower
cost, higher resolution and the lack of requirement for the correct orientation of CTCs on
a slide. Nevertheless, WGS for each patient also requires amplification of a WBC as a
control to properly compare CNVs in each patient, which does raise the cost per patient.
Currently, the multiplex ligation-dependent probe amplification (MLPA) technique is
used to assess the copy number status of chromosomes 1p, 3, 6, and 8. The cost of each
MLPA test is approximately $30 (Australian dollars). Multiple positive controls and
normal DNA controls need to be run at the same time. Further increases in cost are derived
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from running only 1-2 samples at a time given the low frequency of the disease and the
need for a fast turnaround time. Further increases in cost are derived from running only
1-2 samples at a time given the low frequency of the disease and the need for a 00fast
turnaround time. The cost of our methodology is higher, at approximately $190
(Australian dollars) a sample, noting that multiple CTCs are taken per patient, including
a single PBMC. Although the cost of our methodology is high on a per sample basis, it
reduces the reliance on a trained surgeon to acquire tissue, prevents any cost if there are
complications from surgery, reduces morbidity, and provides more information about the
genotype of the patient. Although beyond the scope of this study, WGA-DNA could
possibly be used to detect mutations in genes that can stratify patients into more precise
prognostic categories if required, or can be used to detect isodisomy of chromosomes
using allelic fraction.
In summary, our study demonstrates that isolation, WGA, and low-pass WGS harbours
little artefacts or aberrations and therefore the cells isolated may provide an easier and
safer alternative ‘liquid biopsy’ of the patient primary tumour. Insights into the genomic
characteristics of primary tumours provides crucial prognostic information that can be
used to refer patients to clinical trials, allows more routine monitoring for metastatic
disease, and provides opportunities for the use of potential adjuvant therapies to prevent
metastatic disease.
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Figure Legends
Figure 1: Quality Control of Whole Genome Amplified DNA. a) 1 and 20 - genomic
DNA ladder; 1 – positive PCR control; 3-5, 7-9, 11, 13, 15-18 –high quality WGA-DNA;
6, 10, 14 – poor quality WGA-DNA.; and 19, PCR negative control. New WGA product
was made to replace the DNA in lanes 6, 10, and 14 to ensure all 4 amplicons were present
before sequencing. b) Left – High quality WGA-DNA with the majority of fragments
centred around 400bp in length; right – poor quality WGA-DNA with the majority of
DNA fragments lower than 400bp in size.
Figure 2: Effects of PicoPlex Whole Genome Amplification on the Genomic
Landscape of Uveal Melanoma Cells. UM cell lines MP38, MP41, and MP65 plus a
healthy donor had gDNA extracted and sequenced along with gDNA amplified using
PicoPlex and Picoplex WGA-DNA from 3 single cells from the respective cell line /
donor, a) MP38, b) MP41, c) MP65, and d) a healthy donor. The whole genome amplified
genomic DNA and individual cells all show concordance with the respective genomic
DNA. Minor changes to cell line genomic profiles, such as gain in 6p and 14p in MP38
PicoPlex Cell 3 when compared to the gDNA, may be the result of the stochastic effects
of cell culture rather than artefacts from the kit.
Figure 4: Repli-G Whole Genome Amplification on the Genomic Landscape of
Uveal Melanoma Cells. UM cell line MP41 had genomic DNA extracted and sequenced
a) along with DNA amplified from single cells b-d) by Repli-G. The DNA product
produced was sequenced alongside MP41 genomic DNA. Each of the 3 cells displays
concordance with the sequenced genomic DNA, however the sequenced cells appear to
have more alterations in CNV between bins when compared to their PicoPlex alternatives
(Figure 3) such as aberrant gains/losses in chromosomes 4p, 5, 8, 16, 19, and 20 in MP41
Repli-G Cell 2 (Figure 6c).
Figure 5: Assessment of Cell Processing on Genomic Quality. To test whether
processing the cells would affect the genomic profile of the cell after amplification with
PicoPlex we sequenced a) MP41 gDNA, b) 1 fixed MP41 cell, and c-f) 3 fixed,
permeabilised, and stained MP41 cells and 1 healthy donor PBMC. We found that after
immunomagnetic isolation, fixation in 4% paraformaldehyde caused no aberrations to the
genomic profile of the cell, and that fixation, permeabilisation, and staining had minor
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alterations however the prognostic information was still clearly visible, however, there
were alterations in chromosomes such as 2 and 12.
Figure 6: Genomic Profile of a Single Circulating Tumour Cell Captured in a
Patient with Primary Uveal Melanoma. a) Example of CTC captured. CTCs are heavily
coated in immunomagnetic beads and fluoresce green, whereas PBMCs have few beads
and fluoresce red. Image taken at 200x magnification. b) A single CTC found in a patient
with primary UM was found after immunomagnetic isolation, fixation, permeabilisation,
and staining. The CTC was captured and amplified using PicoPlex WGA and underwent
low-pass WGS. The resultant genomic profile indicated a distinct gain of chromosome 8
whilst the other chromosomes remained diploid, with several other chromosomes
appearing to trend toward a detectable gain.
Supplementary Figure 1: Cell Synchronisation by Serum Depletion: Histograms
displaying cell cycle gating and per cent of cells in each cell cycle phase. “MP41 Control”
shows ~ 12.2% in S phase whilst “MP41 Starved” with serum depletion only had ~5.2%
of cells in S phase.
Supplementary Figure 2: Representative results of ddPCR histograms. GNA11
Q209L assay was tested in samples amplified by a) Repli-G and b-c) PicoPlex. Blue dots
represent mutant DNA positive drops, green dots represent wildtype DNA positive drops,
orange dots represent both positive for mutant and wild type DNA, and black dots
represent empty droplets. Loci are more consistently amplified in Repli-G samples a) than
PicoPlex samples b-c).
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Supplementary Data
Supplementary Method
Cell Cycle Synchronisation
Prior to isolating and capturing single cells from UM cell lines for WGA, their cell cycles
were synchronised to reduce the probability of capturing cells in S-phase, which can lead
to the detection of DNA imbalances. For this, cells were cultured with serum-depleted
RPMI 1640 for 16-18 hours at 37°C in a humidified 5% CO2 incubator. To evaluate that
cells were synchronised we compared MP41 cells that were cultured in RPMI 1640
medium containing FBS and MP41 cells that were cultured in serum-depleted RPMI 1640
medium. MP41 cells were harvested using 5mM EDTA in RPMI 1640, washed twice
with PBS, and fixed using 70% Ethanol in distilled water. Cells were incubated with
propidium iodide and RNase A (Dako) for 10 minutes, washed 3 times in FACS buffer
(PBS with 0.1% BSA, 25mM HEPES, 1mM EDTA, pH 7.0) prior to flow cytometric
analysis on a Gallios Flow Cytometer (Beckman Coulter) and analysed with the Kaluza
software package (Beckman Coulter).
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6.0 General Discussion
The ability to predict the metastatic risk of patients with primary UM is essential for
delineation of UM patients at higher risk, to provide personalised monitoring strategies
and for the testing and implementation of adjuvant therapies to prevent metastatic disease.
Unfortunately, despite the availability of molecular profiling methods for accurate
prediction of metastatic risk, tumour biopsy is only occasionally performed. Vision
threatening complications associated with acquisition of tumour tissue through an
invasive procedure, combined with the current lack of effective therapies precludes many
patients from consenting to the test. Implementation of an alternative, safer method of
predicting patient prognosis is paramount to enable adjuvant therapy clinical trials.
Through this study, we aimed to establish a methodology to make use of CTCs as an
accessible source of tumour material for genetic profiling and prognosis of UM (Figure
14). First, we evaluated melanocyte, melanoma, and stem cell markers on a primary UM
TMA and 5 UM cell lines to find markers that were highly expressed. After determining
5HT2B, ABCB5, gp100, MCAM, and MCSP were suitable extracellular markers for
targeting UM cells, we tested their rate of capture in UM cell lines. We discover that
certain markers provided a low (5HT2B and ACBC5) and others a moderate (gp100,
MCAM, and MCSP) capture rate. Furthermore, we used UM cell lines to validate that the
methods of processing the cells for detection of CTCs followed by WGA does not cause
changes to the genomic profile of the cell, when assessed by WGS. Once these criteria
had been established we determined that single CTC isolation was an effective means of
determining CNVs found in UM.

Figure 14: Pipeline of Circulating Tumour Cell Analysis in Patients. Pipeline of
utilising CTCs as an alternative to a biopsy. Blood is drawn prior to radiation plaque
insertion, followed by isolation and capture of CTCs, followed by WGA and WGS of
captured CTCs WGS data is analysed to give a whole genome CNV report.
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Capture and identification of UM CTCs poses significant challenges. Previous literature
indicates that single markers such as MCSP (Suesskind et al., 2011) and MCAM (Bande
et al., 2015) alone are not sufficient for a viable alternative to tissue biopsy. More recently,
Tura et al (2014) demonstrated that by using two markers, CD63 and surface gp100, that
they could capture a median density of 3.5 CTCs with a range of 0-10.2 cells per 10 mL
of blood in 93.5% of patients with primary UM. This result demonstrated that a multimarker immunomagnetic enrichment protocol was capable of significantly improving
CTC capture in patients. Using this knowledge, we added surface gp100 (NKI/BETEB)
to the multi-marker capture of CTCs. Conversely, although CD63 is a highly important
protein in melanogenesis (van Niel et al., 2011), and highly expressed in UM (CoolsLartigue et al., 2008), we opted to avoid CD63 due to its high expression on nonmelanoma cells (Human Protein Atlas available from www.proteinatlas.org, (Uhlen et
al., 2015)) and microvesicles (Andreu and Yáñez-Mó, 2014), which may lead to higher
background of non-melanoma cells/microvesicles captured. This could confound the
analysis of single CTCs by contaminating them with other sources of extracellular DNA.
Therefore, we targeted markers that are primarily expressed in melanocytes, melanoma,
and stem cells to avoid this issue. Our preliminary data suggests that our multi-marker
panel, comprising of 5HT2B, ABCB5, surface gp100, MCAM, and MCSP is suitable for
capturing CTCs in patients, although analysis of a large cohort of patients using our multimarker panel is required to fully determine the capture rate.
Although we expect that our multi-marker approach will increase CTC capture rates, one
noticeable limitation of analysing CTCs to predict patient prognosis, is that these may not
be found in all patients. It is important to note that implementation of a CTC based test
does not preclude patients from having the biopsy. The blood test should be performed
prior to plaque insertion and if no CTCs are captured from the patient’s blood sample,
there is still the option of a biopsy at the time of surgery. Therefore, our proposed pipeline
of analysing single CTCs supplements the current standard of care rather than offering a
replacement.
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If CTCs are not found in the sample patients can opt for a biopsy which provides several
options for analysis, after extraction of the DNA; i) the biopsy can be whole genome
amplified and sequenced for detection of CNVs across the genome such as the example
shown in Figure 15, ii) MLPA can be performed to detect CNVs in chromosomes 1p, 3,
6, and 8, or lastly, iii) RNA can be extracted and gene expression profiling can be used to
segregate patients into class Ia, Ib, or II (Figure 15). Moreover, DNA amplified could in
future studies be used to detect mutations in BAP1, SF3B1, or EIF1AX to finer segregate
patient prognosis.

Figure 15: Proposed Circulating Tumour Cell ‘Liquid Biopsy’ Pipeline. Proposed
pipeline of CTCs for prediction of patient prognosis. After blood collection and isolation
of CTCs, WGA and WGS would be performed to detect CNV changes associated with
prognosis. If no CTCs are found, patients are still able to request a biopsy at time of
radiation plaque insertion. DNA or RNA would be extracted, followed by either i) WGA
and WGS, or ii) MLPA to detect CNV changes associated with prognosis, or iii) gene
expression analysis of RNA to segregate patients into class Ia, Ib, or II.
Peripheral venous blood is a highly accessible, minimally invasive, and safe method of
acquiring blood used for ‘liquid biopsies.’ However, recently it has been shown that
arterial blood may harbour more CTCs than venous blood, with CTCs detected in 100%
of metastatic UM patients (Terai et al., 2015). Generally, arterial blood is more difficult
to acquire, and more invasive for the patient, but the overall benefit may be greater than
the risk, especially when compared to the intraocular biopsy. Interestingly, Terai et al.
(2015) used the CellSearch system for detection of CTCs which employs MCAM based
capture and MCSP detection. This may indicate that similarly to current findings in
venous blood (Tura et al., 2014; Tura et al., 2016), a multi-marker immunomagnetic panel
might have a greater benefit in arterial blood by increasing the number of CTCs detected
in each patient.
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Whilst CTCs constitute a source of genetic material for use in predicting patient prognosis
through CNVs, there has been no correlation between the numbers of CTCs quantified
and patient outcomes (Suesskind et al., 2011; Tura et al., 2014). In contrast, whilst we
have shown ctDNA is rarely detectable in patients with primary UM, previous studies
have detected ctDNA in 84% of patients with metastatic disease (Bidard et al., 2014).
Therefore, tracking ctDNA in patients with tumours at a high risk of metastasizing may
provide early indications that metastatic lesions have arisen, most likely within the liver
(COMS-15, 2001). In other cancers, ctDNA has been used to measure tumour mutational
load (Murtaza et al., 2013), residual disease (Diehl et al., 2008), resistance to therapy
(Gray et al., 2015b), tumour burden (Bettegowda et al., 2014), tumour relapse (GarciaMurillas et al., 2015), and CNVs (Heitzer et al., 2013b). Fortunately, the majority of UM
have hot spot mutations in GNAQ, GNA11, PLCβ4, or CYSLTR2 which are easily
detectable using technologies such as ddPCR. This combination of all these markers
could allow for analysis of ctDNA without prior knowledge of the mutational status of
the tumours in the majority of cases as approximately 94% of patients have a mutation in
these hotspots (Moore et al., 2016). However, a negative result always will have to be
regarded as negative only for the tested mutations and not the lack of ctDNA.
Nevertheless, the use of these mutations enables tracking of ctDNA regardless of whether
a patient’s primary or metastatic lesions were biopsied. Further studies are required to
ascertain whether ctDNA can be used as an early indicator of metastatic disease and that
it is comparable or superior to current tests such as positron emission tomography or
magnetic resonance imaging.
Recent data has shown that fine-needle biopsies via transcorneal, transscleral, or
transvitreal have a true positive rate of 92% when using cellularity to diagnose UM.
Moreover, prognostication using FISH could only be performed on 84.6% of fine needle
biopsies due to the lack of cells (Singh et al., 2016). Factors that improved prognostic
yield were enucleation, larger tumour size, and distance from fovea. Additionally,
patients who required transvitreal or transcorneal biopsy had a greater rate of failure when
compared to transscleral (68.8%, 87.5%, and 98.6% respectively) (Singh et al., 2016). It
is currently unknown the failure rate of using CTCs as a minimally invasive liquid biopsy,
but we envisage it to be used as an alternative to tumour biopsy. If the liquid biopsy
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produces inconclusive results an intraocular biopsy can still be performed at the time of
radiation plaque insertion.
Mutations in BAP1, SF3B1, and EIF1AX can further stratify patients into more refined
prognostic classes (Field et al., 2016). Detection of these mutations in PicoPlex WGA
proved to be challenging, due to the size of PicoPlex product (~400bp), and that targeted
or whole exome sequencing requires primers to synthesise fragments for sequencing and
these may not overlap correctly in the small DNA fragments produced by PicoPlex to
produce an amplicon. Our preliminary data in testing targeted sequencing of a PicoPlex
WGA-DNA using Ampliseq gave extremely erroneous results. Furthermore, primerless
whole genome sequencing at a suitable depth to analyse mutations is currently
prohibitively expensive. Fortunately, sequencing costs are continually decreasing,
according to the National Institute of Health (NIH), and further refinement of high
throughput sequencing may further reduce the per-genome cost of sequencing
Overall, the primary objective of a less invasive method of determining patient prognosis
is to reduce the complications associated with biopsy, and to encourage more patients to
determine their prognosis. If patient prognosis has been determined the implementation
of neo-adjuvant therapies, adjuvant therapies, closer follow-up, or even entry into clinical
trials can occur. Current clinical trials into adjuvant therapies, targeted therapies, and
immunotherapies all require prior information on a patient’s risk of developing metastatic
disease (Appendix 8.3 & 8.4). Recent clinical trials show slight benefits to patients
utilising targeted therapies (Selumetinib, 2013), whereas immunotherapies generally
have little to no effect (Algazi et al., 2016; Moser et al., 2015). Adjuvant therapy has
previously been reported to have survival benefits in various cancers, such as breast (Goss
et al., 2005) and colon (Ribic et al., 2003; Schmoll et al., 2015) cancers. Although there
is no evidence that current adjuvant therapies for UM have any impact on survival of
patients with high risk of developing metastasis, current and future trials of different drugs
may find a survival benefit or preferably preclude metastatic disease in patients, and
therefore it would be beneficial for all patients to know their prognosis so that they may
partake in clinical trials, or therapies which may provide them with improved quality of
life.

83

84

6.1 Limitations
A limitation of this study is the sample cohort. As UM is a rare disease, in an area with a
low population (approximately 1.8 million people in Perth, Western Australia) it is
difficult to gain the appropriate numbers for in-depth analysis. A multicentre study from
various locations in Australia would be crucial for determining the concordance between
the genetic characteristics of CTCs and their correlation with the primary tumour and
patient prognosis.
Similarly, due to the timeframe of a Masters project, and first having to validate all the
methods used to analyse single CTCs, we were only able to capture 1 CTC in a single
patient. To further validate whether CTCs can represent the primary tissue and thus the
risk of metastatic risk in patients, further CTC analysis in a larger cohort of patients is
required.
In addition, the use of a TMA for the primary tissue may have caused an under or over
representation of the immunopositivity of proteins, due to the 1 mm cores. Although care
was taken to acquire tissue in histologically distinct areas of the tumour, the overall small
size of the cores gives a small snapshot of the tumour. For example, if a marker is highly
expressed on the tumour invading front, it may be under represented in our study, as the
edges of the tumours were avoided. This is however, offset by using multiple cores per
tumour in different areas. TMA’s are routinely used due to their benefits of screening a
higher number of patients more efficiently and we found the TMA to be of significant
benefit for assessment of markers.
Whilst we have shown in cell lines PicoPlex introduces only minor changes to ploidy
across the genome, if these changes occur in chromosomes relating to metastatic risk it
could alter the prognostic call. This would introduce false positive results. Fortunately,
our testing indicates that the amplification method is quite robust and unless the reaction
failed, the resultant WGA-DNA harboured a match to the original material. It is also
important to note an additional limitation to our study was that the amplification of cells
unfixed, fixed, and fixed-permeabilised and stained was performed with different
passages of MP41 cells and the changes could be due to the effects of cell culture. By
attempting to capture more than 1 CTC per patient we aim to obtain consistent
chromosomal CNV across various cells to remove any random CNV introduced as an
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artefact. Nevertheless, in our preliminary data, sequenced PBMCs from patients have all
displayed the correct ploidy. Further studies will provide a larger cohort of sequenced
WGA cells and provide a better indication of the false positive rate.

6.2 Future Directions
Following on from this study we will focus on determining whether CTCs can predict
patient prognosis as do current methods such as gene expression profiling or MLPA,
however these require tissue biopsies. To assess CTC concordance with tissue analysis, a
prospectively designed study would be carried out, where peripheral blood samples and
matched biopsies would be taken and genotyped prior to therapy of the primary tumour,
and patients would be followed over a >3-year period.
In addition, future studies will involve pre-clinical mouse models where dissemination of
CTCs from the primary tumour will be modulated with various drug combinations to try
and disrupt metastases forming in the liver. These experiments could provide clear
answers of the potential benefit of adjuvant therapy to prevent metastatic UM in at risk
patients.

6.3 Conclusion
Our study validated 5HT2B, ABCB5, gp100, MCAM, and MCSP as highly expressed in
UM and suitable candidates for capture of CTCs in patients with primary UM.
Furthermore, we validated the use of PicoPlex WGA and low-pass WGS as an effective
means of whole genome CNV analysis of CTCs that have been immunomagnetically
enriched from PBMCs, fixed, permeabilised, and immunostained. Using this pipeline of
a multi-marker immunomagnetic enrichment protocol, we were able to determine in a
single patient a gain of the chromosome 8, a poor prognostic feature in UM.
It is clear that our study has established an effective means of utilising CTCs to detect
chromosomal aberrations associated with metastatic risk in UM. Future studies will
validate this methodology in which CTCs can be used as an alternative source of tumour
genetic material from which patient prognosis can be derived, therefore potentially
reducing complications associated with biopsy of the eye, while providing more patients
at a high risk of developing metastases the option of closer follow-up, and possible
adjuvant therapy options.
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8.0 Appendices
8.1 Study Ethics Information and Consent Form
PA RT I C I PA N T

I N F O R M AT I ON S H E E T

Identification of markers for diagnosis and prognosis of cancer

Prof Mel Ziman, Prof Michael Millward, A/Professor Fred Chen, Dr Tim Isaacs, Dr Chris
Quirk, Dr Adnan Khattak, Dr Lester Cowell, Dr Graham Potter, Dr David Prentice, Mr
Mark Lee, Prof Robert Pearce, Ms Anna Reid, Mr James Freeman, Dr Elin Gray, Ms
Pauline Zaenker, Ms Kit Dufall, Dr Johan Poole-Johnson, Dr Arif Anwar, Mrs Ashleigh
McEvoy, Dr Henry Law, Dr Carlos Aya-Bonilla, Mr Aaron Beasley.
Please take time to read the following information carefully and discuss it with your
friends, family and general practitioner if you wish. Ask us any question if some part of
the information is not clear to you or if you would like more information. Please do this
before you sign this consent form.
Who is funding this study?
NHMRC, Cancer Research Trust, Edith Cowan University
Contact persons:
Should you have questions about the study you may contact:

Prof. Mel Ziman

Phone No.

6304 3640 Mobile: 0419929851

All study participants will be provided with a copy of the Information Sheet and Consent
Form. They may keep the information sheet for their personal records.
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You may decide to be in the study or not take part at all. If you do decide to take part in
this study, you may stop at any time. However, before you decide, it is important that
you understand why this research is being done and what it will involve.
Whatever your decision, this decision will not lead to any penalty or affect your regular
medical care or any benefit to which you are otherwise entitled.
The following information sheet will explain the study and will include details such
as:
o Why this trial might be suitable for you;
o The possible risks (side-effects) and benefits of the new test;
o The type, frequency and risks of any medical tests or procedures required by the
trial;
o The nature of your participation including how many visits you will make to the
hospital
o Your rights and responsibilities
o Who is funding this study

111

What is the purpose of the study?
This study is a research project in which we are investigating circulating tumour cells
(CTCs), gene expression (RNA), cell free DNA and proteins in the peripheral blood of
patients with cancer relative to these markers in tumour tissue and in control bloods. It is
anticipated that changes in cellular, genetic or protein markers in the blood of patients are
indicative of tumour presence (diagnostic) or may provide information on patient
outcome or tumour progression (prognostic) or response to treatment.
We will isolate and quantify circulating tumour cells and genetic material (DNA and
RNA), as well as proteins and sugars from the blood of all participants. We will
characterise the cells, genes and proteins and sugars for markers of cancer.
If we find that there are circulating tumour cells in your blood, we may ask your consent
to isolate and grow the isolated circulating tumour cells and use them for laboratory
experiments. We may ask your consent to access a small amount of your archival tumour
tissue stored at Pathology Centres or fresh tissue at the time of surgical removal or biopsy
for routine pathological diagnosis. We only require a small portion of your tumour that is
additional to that required for pathological diagnosis. Tumour tissue may include both
primary and metastatic tissue samples where appropriate. DNA from your circulating
cells and tumour tissue will be compared for mutation analysis. We will also isolate
proteins from your blood for analysis relative to control samples.
1500 participants will be invited to participate.
Why is this study suitable to me?
You have been invited to participate in this study because you have been diagnosed with
cancer.
How long will I be in this study?
The study will be conducted over a five year period. As a patient you will be asked to
provide a blood sample at the time of surgical removal of your tumour or at the
commencement of additional therapy and at follow-up.
As a patient you may also be asked to provide consent for us to access a small amount of
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your tumour tissue which has been stored at Pathology Centres after being used for
diagnosis. Alternately you may be asked to provide a small sample of fresh tumour tissue
at time of removal or biopsy of your tumour.
What will happen if I decide to be in this study?
If you agree to participate you will be asked to provide blood samples at the time of
surgical removal of your tumour or before and during treatment, where appropriate. You
will be asked to provide additional blood samples at the time of routine clinical followup visits to your clinician.
The amount of blood required for this study is small (approximately 40 ml per visit).
Blood will be drawn into 8 x 4 ml EDTA blood tubes and 1 x 4 ml SST tube, for isolation
of the circulating cells and for analysing genes, proteins and sugars in your blood.
Generally you will not be contacted between visits. If you require general information
about the research at any time then you are able to contact the researchers should you
wish to do so. Contact details are provided in the information sheet.
Your blood will be tested relative to blood from other participants. Your samples are only
identifiable by a coded number, and the researchers performing the tests will not know
which samples are yours.
Your samples will be stored in locked freezers in secure research laboratories during the
research study and will be discarded five years after completion of the study or upon your
written request.
Are there any reasons I should not be in this study?
The clinical staff collaborating in this study will discuss the research with you in detail
and will ensure that this trial is both safe and appropriate for you.
What are the costs to me?
There will be no additional costs over and above your visits to the doctor. Blood will be
taken at the hospital or private clinical practice or at Edith Cowan University when and
where you visit your doctor for treatment and follow-up visits. Your tumour tissue may
be required for comparison with your blood sample and your tissue will be accessed
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through clinicians and pathology centres and will be extra tissue that is not required for
diagnosis.
What are the possible benefits of taking part?
The results of these studies may be of interest to you and your family and you may decide
whether or not the information may be disclosed to your family. You will be provided
with the results of the project in general. However, the research will not provide you with
any detailed information about your health or genetic diseases in general.
Donation of your sample may assist researchers to provide a more detailed and specific
diagnosis of cancer now and in the future and to assist with improvements in treatment of
cancer.
How will my safety be ensured?
In this study, the samples that you provide are blood samples and you may also be asked
to provide permission to access a small quantity of your tissue sample(s). There is very
little risk to you as only a small volume of blood is required for the test and the tissue has
already been removed during surgery. However ple
ase do not hesitate to contact the study coordinator or your doctor in relation to any
adverse effects you think you are experiencing. If the effects are severe enough, the doctor
may stop your participation in the study.
The study may produce abnormal results in which case your clinician will be notified and
additional clinical tests will be performed if your doctor feels it is in your best medical
interest. When you stop participation in the study you will be clinically assessed as you
were at the beginning of the study.
What alternatives do I have to going on this study?
This study does not affect your treatment. Your treatment will continue in the same
manner whether you decide to participate in the study or not.
You may wish to discuss with your doctor or the researchers how the test will benefit
patient treatment now or in the future.
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What are the possible side effects, risks and discomforts of taking part?
In this study, only a small volume of blood is taken (40 ml), so there is very little risk to
you in this procedure. You may suffer a small amount of discomfort when you donate the
blood sample, like the feeling of a pin prick or bruising.
The likelihood of side effects from donating blood is small, around 1 in 100. However
should you suffer any side effects please tell your doctor immediately about any new or
unusual symptoms that you get.
What if new information comes along during the study?
Sometimes new information becomes available as a study progresses. You will be told
about any information that could be important to you and to your decision to continue in
the study. If you then want to continue in the trial, you may be asked to sign a revised
consent form.
Stopping the study early:
Sometimes a trial needs to be stopped early because of safety concerns, because the trial
is not effective enough, or for other reasons. If this occurs, the reasons will be explained
to you and your treatment will continue as it would have without the test. Your treatment
will not be influenced by the test in any way.
What happens at the end of the study?

At the end of the study your visits to your doctor will continue and your treatment will
not be affected by the outcome of the research.
What if something goes wrong?
You will receive the best medical care available during and after the test, but because
these are still relatively new tests, unexpected results may be obtained. In the unlikely
event of risks to your health being identified then you will be provided with the necessary
care.
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Medical treatment will be provided at no cost to you for research-related harm. The term
“research-related harm” means both physical and mental injury caused by the procedures
required by the trial.
Your participation in this study does not prejudice any right to compensation which you
may have under statute or common law.
Will my taking part in this study be kept confidential?
The researchers will need to collect personal data about you, which may be sensitive, such
as your relevant health information. This includes clinical records relating to the diagnosis
and treatment of your cancer. The researchers may also need to get some of your health
information from other health service providers, e.g. another hospital, pathology
laboratory, radiographer, GP or other medical specialist.
Any personal or health information will be kept private and confidential. It will be stored
securely and only authorised persons, who understand it must be kept confidential, will
have access to it. Your study details will be given a number so that your identity will not
be apparent. The trial records will be kept at The School of Medical Sciences at Edith
Cowan University during the study and in a locked archive for at least 10 years from the
time the study is closed, and will be destroyed by incineration thereafter.
Authorised representatives of the researchers, the investigating doctors, the Hospital or
University Human Research Ethics Committees, Research Governance and other
regulatory bodies may require access to your study records for study procedures and/or
for data analysis. Your sample may be sent to people in other states or other countries for
analysis, however your sample will be identified by a sample number only, and your name
and personal details will not be provided. In all cases when dealing with your sample,
personal or health information, researchers are required to comply with privacy laws that
protect you.
The result of the research will be made available to other doctors through medical journals
or meetings, but you will not be identifiable in these communications. By taking part in
this study you agree not to restrict the use of any data even if you withdraw. Your rights
under any applicable data protection laws are not affected. Your sample will be destroyed
upon written request if you withdraw from the study.
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Will I find out the results of the study?
The value of the research is not known at this time. You will be notified of the results of
the research in general terms at your request and the outcomes of the research as a whole
may be provided to you upon completion of the project.
Who has reviewed the study?
The Sir Charles Gairdner Hospital Human Research Ethics Committee and the Edith
Cowan University Human Research Ethics Committee have reviewed this study and have
given approval for conducting this research trial. In doing so this study conforms to the
principles set out by the National Statement on Ethical Conduct in Research involving
Humans and according to the Good Clinical Practice Guidelines.
If you have any concerns or complaints and wish to talk to an independent person, please
contact:
Research Ethics Officer

Phone: 6304 2170

Email: research.ethics@ecu.edu.au
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CONSENT FORM

Identification of markers for diagnosis and prognosis of cancer

Prof Mel Ziman, Prof. Michael Millward, A/Professor Fred Chen, Dr Tim Isaacs, Dr
Chris Quirk, Dr Adnan Khattak, Dr Lester Cowell, Dr Graham Potter, Dr David Prentice,
Mr Mark Lee, Mr Robert Pearce, Ms. Anna Reid, Mr. James Freeman, Dr Elin Gray, Ms.
Pauline Zaenker, Ms Kit Dufall, Dr Johan Poole-Johnson, Dr Arif, Anwar, Ms Ashleigh
McEvoy, Mr Aaron Beasley.
.

Participant Name:_________________________________________

Date of Birth: _______________

Address: ------------------------------ Phone Number:----------------------------------

1. I have been given clear information (verbal and written) about this study and have
been given time to consider whether I want to take part.

2. I have been told about the possible advantages and risks of taking part in the study
and I understand what I am being asked to do.
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3. I have been able to have a member of my family or a friend with me while I was told
about the study. I have been able to ask questions and all questions have been
answered satisfactorily.

4. I know that I do not have to take part in the study and that I can withdraw at any time
during the study without affecting my future medical care. My participation in the
study does not affect any right to compensation, which I may have under statute or
common law.

5. I agree to take part in this research study and for the data obtained to be published
provided my name or other identifying information is not used.

6. I provide consent for my medical history to be made available to the researchers.

7. I provide consent for the researchers to access a small sample of blood (40mls) and if
necessary, my tumour tissue that is additional to that required for diagnosis.

8. I provide consent for my circulating tumour cells isolated from my peripheral blood
to be used in laboratory experiments.

9. I understand that my sample and associated data may be used for future cancer
research by researchers at Edith Cowan University in collaboration with researchers
from other universities.

10. I consent to blood and tissue samples being taken and donate that blood and tissue
absolutely for testing and research into cancer and related health areas.
119

11. I understand that access to my blood donation and tissue sample for research will only
be released where the research project that wishes to use my blood donation and/or
tissue sample has been approved by an Ethics Committee

If you are unclear about anything you have read in the Participant Information Sheet or
this Consent Form, please speak to your doctor before signing this Consent Form.

Name of Participant

Name of Investigator

Signature of Participant

Date

Signature of Investigator

Date

The Sir Charles Gairdner Hospital and Edith Cowan University Human Research Ethics
Committees have given ethics approval for this study. If you have any concerns you can
contact the Chief Investigator, Prof Mel Ziman: Phone (08) 63043640

All study participants will be provided with a copy of the Information Sheet and
Consent Form for their personal records.
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8.2 DecisionDx-UM Genes
Symbol

Gene

Regulation in class
II

CDH1

E-cadherin

Up

ECM1

Extracellular matrix protein 1

Up

E1F1B

Eukaryotic translation initiation factor 1B

Down

FXR1

Fragile X mental retardation autosomal homolog 1

Down

HTR2B

5-hydroxytryptamine (serotonin) receptor 2B

Up

ID2

Inhibitor of DNA binding 2

Down

LMCD1

LIM and cysteine-rich domains 1

Down

LTA4H

Leukotriene A4 hydrolase

Down

MTUS1

Microtubule-associated tumor suppressor 1

Down

RAB31

RAB31, member RAS oncogene family

Up

ROBO1

Roundabout, axon guidance receptor 1

Down

SATB1

SATB homeobox 1

Down

MRPS21

Mitochondrial ribosomal protein S21

Normal (Control)

RBM23

RNA binding motif protein 23

Normal (Control)

SAP130

Sin3A-associated protein

Normal (Control)
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8.3 Clinical Trials of Targeted Therapies for UM
ClinicalTrials.gov

Compound Tested

Target

Identifier
NCT01430416

Mutation
Rationale

AEB071

PKC

GNAQ/11

Sunitinib

MEK

GNAQ/11

NCT01252251

Everolimus

mTOR

GNAQ/11

NCT01587352

Vorinostat

HDAC

BAP1

Sorafenib

RAF-kinases

GNAQ/11

NCT01801358

MEK162

MEK

GNAQ/11

NCT01143402

Selumetinib

MEK

GNAQ/11

NCT01835145

Cabozantinib

MEK, KIT

GNAQ/11

NCT00104884

Romidepsin

HDAC

BAP1

NCT01801358
NCT01551459
NCT01005472

NCT00121225
NCT01377025
NCT01893099
NCT00329641
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8.4 Adjuvant Therapy Clinical Trials for High Risk Patients
Clinicaltrials.gov

Compound Tested

Identifier
NCT02843386

NCT02068586

Fotemustin

Sunitinib

Primary Outcome

Secondary Outcome

Measure

Measures

Metastasis free

Overall survival [3yrs]

survival [3 yrs]

Safety

Overall survival [2 yrs]

Relapse free survival

Valproic acid

[2yrs]
Tolerability

NCT01983748

Autologous dendritic cells

Prolongation of disease

Prolongation of overall

loaded with autologous

free survival [36 mths]

survival [36 mths]

Disease free survival

Safety

tumour RNA
NCT01100528

Recombinant interferon alfa2b

Relationship between

Dacarbazine

plasma biomarkers of

Laboratory biomarker

immune function and

analysis

tumour invasion and
clinical outcome

NCT02223819

Crizotinib

Relapse free survival

Overall survival [36

[36 mths]

mths]
Disease specific
survival time [36 mths]
Prevalence of
treatment
discontinuation due to
toxicity [48 wks]
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8.5 COMS Staging System
Measure

Small

Medium

Large

Apical Height

1.0-3.0 mm

3.1-8.0 mm

>0.8 mm

Basal Diameter

5.0-16.0 mm

≤16.0 mm

>16.0 mm when apical
height ≥2 mm

(COMS-5, 1997; COMS-17, 2001)
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8.6 AJCC Staging System
Location

Iris

Ciliary Body
and Choroid

Both

Tumour
Stage

Description

T1

Limited to iris

T1a

Limited to iris and <3 clock hours in size

T1b

Limited to iris and >3 clock hours in size

T1c

Limited to iris with secondary glaucoma

T2

Extending into ciliary body, choroid or both

T2a

Confluent with or extending into ciliary body, choroid or both and has secondary glaucoma

T3

Scleral extension

T3a

Confluent with or extending into ciliary body, choroid or both with scleral extension

T4

Extrascleral extension

T4a

Extrascleral extension ≤5 mm in diameter

T4b

Extrascleral extension ≥5 mm in diameter

T1

Tumour size category 1

T1a

No ciliary body involvement or extraocular extension

T1b

Ciliary body involvement

T1c

No ciliary body involvement, extraocular extension ≤5 mm in diameter

T1d

Ciliary body involvement, extraocular extension ≥5 mm in diameter

T2

Tumour size category 2

T2a

No ciliary body involvement or extraocular extension

T2b

Ciliary body involvement

T2c

No ciliary body involvement, extraocular extension ≤5 mm in diameter

T2d

Ciliary body involvement, extraocular extension ≥5 mm in diameter

T3

Tumour size category 3

T3a

No ciliary body involvement or extraocular extension

T3b

Ciliary body involvement

T3c

No ciliary body involvement, extraocular extension ≤5 mm in diameter

T3d

Ciliary body involvement, extraocular extension ≥5 mm in diameter

T4

Tumour size category 4

T4a

No ciliary body involvement or extraocular extension

T4b

Ciliary body involvement

T4c

No ciliary body involvement, extraocular extension ≤5 mm in diameter

T4d

Ciliary body involvement, extraocular extension ≥5 mm in diameter

T4e

Any tumour size category with extraocular extension ≥5 mm in diameter

N0

No regional lymph node metastasis

N1

Regional lymph node metastasis

M0

No distant metastasis

M1

Distant metastasis

M1a

Diameter of largest metastasis is ≤3 cm

M1b

Diameter of largest metastasis is 3.1-8 cm

M1c

Diameter of largest metastasis is ≥8 cm

(Edge et al., 2010)
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